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The World Congress of Psychiatric Genetics (WCPG) has become an annual event
since the early 1990’s sponsored by the International Society of Psychiatric Genetics
(ISPG). Each year the latest published and unpublished findings are aired for
discussion by representatives of the majority of research programs on this topic
world-wide. The 2007 congress was held in New York City and attracted over 1000
researchers. The topics emphasized included results from whole genome association
studies, the significance of copy number variation and the important contributions of
epigenetic events to psychiatric disorders. There were over 20 oral sessions devoted
to these and other topics of interest. Young investigator recipients of travel awards
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INTRODUCTION
The following series of short reports summarizes the information presented and
discussed during the oral sessions of the XVth World Congress of Psychiatric
Genetics (WCPG) held at the Marriott Marquis Hotel in New York City October 7th to
11th 2007. Often times, while there is a record of abstracts written several months
before presentations, there is no written recording of what has happened during the
sessions for those meeting attendees who were participating in other overlapping
sessions or for those individuals who were unable to attend the conference and are
interested in this field. Thus, at the 2007 WCPG a new rapporteur program was
established in order to provide a recording for the written record of what transpired
during these interesting and intense days. Rapporteurs were selected from the group
of student travel awardees who volunteered to take on this task as one of the ways
they would participate in the congress. All reports are the impressions and
interpretations of the Rapporteurs and thus the investigators they quote are not
responsible for the accuracy of these reports. We hope to continue publishing
summaries and impressions of young investigators who attend the WCPG each year
and thank those who donated their time to this important effort to summarize the
2007 WCPG.
This year the spotlight seemed to be on results beginning to emerge from very large
multicenter collaborations performing genome-wide association in multiple psychi-
atric disorders, ADHD, autism, schizophrenia and bipolar disorder. In addition there
was a new awareness of the significance of copy number variation throughout the
genome as well as epigenetic events and the creation of an ‘‘epigenome’’ that may
be more crucial in understanding the genetics of brain disorders than simply the
variation in DNA sequence. The field has without question made considerable
progress since the first gatherings of the newly formed field of psychiatric genetics in
the 1980’s; but clearly it still has a long way to go before the mechanisms that
contribute to the development of these uniquely human disorders of thinking and
communication that are at the heart of this field are uncovered.
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1. GENOME-WIDE ASSOCIATION IN BIPOLAR
DISORDER AND SCHIZOPHRENIA
Reported by Marlon Quinones, Amber Baum,
and Lynn E DeLisi
Whole genome-wide association studies (GWAs) were
certainly the highlight of this congress. In previous years
relatively small samples of families were used to try
and define patterns of chromosomal linkage that would
indicate regions for major genes for schizophrenia and
otherpsychiatricdisorders.Thesestudies largely failedto
produce consistent findings and were followed by a var-
iety of candidate gene association studies. However, it
was recently felt that the first generation of studies failed
because, not only were the sample sizes much too small,
but the number of markers used to survey the genome
were clearly not sufficient. Thus with the development of
new chip technology, SNP maps of the genome now
numbering almost a million, and multicenter collabora-
tions a reality, several new GWAs (Genome-Wide
Association studies) are now being reported. The data
presented at this 2007 meeting were just the beginning.
For bipolar disorder, the congress opened with a
plenary session summarizing four major bipolar GWAs
with data analyzed, with others to be reported in the
near future. Nick Craddock (Cardiff University, Wales)
presented results from the Wellcome Trust Case-Con-
trol Consortium (WTCCC) study, which was recently
published in Nature as part of a larger association study
that included six other complex disorders (The Welcome
Trust Case Consortium, 2007). Using 2000 bipolar cases
and 3000 UK controls genotyped on the Affymetrix 500K
chip, the WTCCC found SNP associations of small effect
sizes in novel regions and near plausible gene candi-
dates such as a GABA receptor (GABRB1), a glutamate
receptor (GRM7), and the presynaptic protein synapsin
III (SYN3), although the strongest result, which also
had an odds ratio over 2, was in a novel region on
chromosome 16. Craddock also presented a new meta-
analysis of the WTCCC data and the study from Baum et
al. (see below) which showed that the set of SNPs
reported as replicated in the Baum et al. study had more
significant p-values in the WTCCC sample than would
be expected by chance.
Pamela Sklar (Massachusetts General Hospital and
the Broad Institute, MIT) reported on a study combining
the Systematic Treatment Enhancement Program for
Bipolar Disorder (STEP-BD) sample with a UK sample
(collected by Hugh Gurling’s group at The University
College, London) which totaled 1461 bipolar and 2008
unaffected controls genotyped on the Affymetrix 500K
chip. Gene candidates identified in this study included
Myosin 5B (the protein encoded by this gene is expressed
in dendritic spines) and EGFR. When comparing this
sample’s finding with the WTCCC’s and Baum et al’s
findings, SNPs in the gene DFNB31 (Whirlin) were
found to be associated in all three samples, although the
opposite allele was associated in the WTCCC. Notably,
Dr. Sklar’s combined analysis plus an additional exten-
sion sample of about 1000 individuals also revealed
association to a SNP in the calcium channel, voltage-
dependent, L type, alpha 1C subunit (CACNA1C), a
voltage-dependent calcium channel subunit, which had
a small OR (1.19) but a robust P-value.
Amber Baum (MAP Genetics, NIMH Intramural
Program) reported on a study that used a narrowly-
defined subset of the NIMH Bipolar Disorder Consor-
tium sample and a larger sample collected from
Germany (see below). The initial results, using a DNA
pooling strategy with the Illumina HumanHap550 chip
to genotype a total of 1233 cases and 1439 controls, were
published in May (Baum et al., 2007) and implicated
80 genes. Baum presented new results from a random-
effects meta-analysis based on the Baum et al. and
WTCCC studies. Evidence of association in all three
samples was shown for two SNPs near the genes JAM3
and ZIP3. No support was found in the WTCCC sample
for the most significant SNP reported in Baum et al.,
which resides near the lithium-related gene diacylgly-
cerol kinase eta (DGKH).
Laura Scott (Pritzker Consortium, University of
Michigan) also presented results from the NIMH
Bipolar Disorder Consortium sample. The Pritzker
Consortium genotyped about 1,000 NIMH cases on the
Human Hap550, along with a similar number of
controls. No genome-wide significant findings emerged,
but support was seen for DGKH and a variety of novel
loci. Sven Cichon (University of Bonn, Germany) had
just completed individual genotyping on the Human-
Hap550 of 772 cases and 876 controls, one of the samples
that was pooled in the Baum et al. study. Preliminary
results supported key findings in the published paper
but analyses were ongoing at the time of the meeting.
Looking beyond specific candidates, these 5 GWAS in
BD tell us about where the field is and where it is
heading. There was a unanimous agreement that
collaboration between groups was now more than ever
indispensable to reach the number of subjects required
to identify the likely multiple genes of modest effect sizes
that maybe accounting for the well defined genetic
susceptibility to BD. Also, it was shown that i) meta-
analytical tools provide an excellent opportunity to
harvest results from smaller studies and lead to identi-
fying candidate genes more likely to be replicated in
future studies; ii) studies based on initial pooling of
samples may be a viable alternative to reduce costs dur-
ing initial screening phases; and iii) we may be missing
several SNPs due to the losses during the QC. For
instance, in the study presented by Dr. Sklar, 500,568
SNPs were genotyped using the Affymetrix GeneChip
Human Mapping Array. For analysis only SNPs met a
variety of stringent criteria resulting in a final dataset of
372,193 SNPs. The overall genotyping call rate was
99.4%. This limited coverage may help explain why the
previously closely studied candidate gene studies have
not shown up in GWAs. Nevertheless, with bipolar
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genome-wide association studies, some genes seemed to
standout across independent samples and these will
likely receive considerable attention in follow-up studies,
while other gene associations were found in one sample
and not another. Whether the latter are spurious
findings will be clarified with more future studies.
In another session, five major GWA studies on
schizophrenia were represented, one put together under
the leadership of Pamela Sklar at the Broad Institute,
another from the Wellcome Trust collaboration in the
UK and presented by Michael O’Donovan, another on a
national German sample, presented by Sven Cichon
from Bonn, the fourth from Shanghai led by Lin He and a
USA sample from the subjects who participated in the
CATIE neuroleptic comparison trial. All studies used
either a 500K or greater chip from Affymetrix or
Illumina. The Broad Institute sample consisted of 3800
cases of schizophrenia and 4200 controls, the Wellcome
Trust sample 1600 cases and 3700 controls, while the
German, Shanghai and CATIE samples were smaller
with 493 cases and 1356 controls (German), 200 cases
and 200 controls (Shanghai) and 741 cases and 751
controls (CATIE). While the CATIE sample failed to
show any areas of genome-wide significance, the other 4
had several regions of interest. What was most notable
was that unlike what emerged in independent bipolar
GWAs thus far, with schizophrenia there was no
consistent pattern of significance across studies and
none of these studies implicated as candidates any of the
previously thought of candidate genes, such as neur-
egulin, dysbindin, COMT, BDNF or G72. However,
genome-wide association studies are still in their
infancy and their outcome and usefulness are yet to be
determined. Many of the studies will need to be
combined to yield larger N’s with the knowledge that
diagnosis and clinical information may vary from center
to center producing some level of noise within the data.
While the N’s may need to be substantially higher for
consistent results to emerge, the alternative view that
the epigenome and environmental influence must be
accounted for will need to be aired. The field currently
awaits reports from the NIH Foundation-Pfizer GAIN
program that has as one of its projects genome-wide
association of schizophrenia using over 3000 Caucasian
USA cases and 3000 controls.
Reference
The WellcomeTrust Case Control Consortium. Genome-
wide association study of 14,000 cases of seven common
diseases and 3,000 shared controls. Nature 2007; 447:
661–648.
2. GENOME-WIDE STUDIES OF AUTISM
AND ADHD
Reported by Sophia Docherty
Though the central phenotypes were autism and ADHD,
the aspect which most notably united this group of oral
presentations, as well as a number of the conference’s
other talks, was the attention devoted to the technical
and analytical obstacles encountered when conducting
research on a genome-wide scale. Whilst the study
designs discussed were impressive and will no doubt
yield findings of great import for their fields, with many
of the results presented being far from final, the
suggested methodological approaches – readily applic-
able across most phenotypes – were just as captivating
as the substantive content.
Mark Daly was the first to present his ‘Genome-wide
association study in autism’. His group was instrumen-
tal in the development of the Genome-Wide Human SNP
Array 5.0 (Affymetrix), to combine both SNP and CNV
genome-wide coverage in a single assay. Rather than
simply detecting CNVs, the 5.0 – and now the million
SNP chip 6.0 – also offers quantitative information in
order to generate a CNV genotype. Using this new
platform, Daly studied 751 families, each comprising
two or more effected siblings, drawn from the Autism
Genetic Resource Exchange (AGRE). A CNV was
detected along an identical 600Kb stretch of 16p in 5
patients, but was not seen in their families. A CNV at
this position was also detected in a further 8 patients in 3
families, where it was shown to segregate with autism.
In a separate screen of 512 clinically referred children
with developmental delay ASD, a deletion at this stretch
was detected in 5 children, a duplication in 4 more. No
deletion or duplication was found in any of the 450
controls used.
Daly’s finding of a CNV present in 1–2% of the autism
cases studied seems consistent with the recent litera-
ture suggesting a role for de novo CNVs in autismi.
However, this was the only highly recurrent de novo
CNV found, and upon discussion with the panel we were
reminded that until the base rate of de novo CNV
mutations throughout the normal population has been
gaged via analysis of several generations of control
populations, causal relationships can not be concluded.
Preliminary SNP analyses were also presented, with 51
SNP associations at p< 104, 6 at p<105, a robust
association in chromosome 1 and promising findings
in the DAOA gene mentioned. However, despite the
completion of basic quality control measures in PLINK
and Birdseed (2.0) which reduced the number of SNPs in
the study from 470,000 to 400,000, a good deal more data
cleaning is required before Daly would be ready to
present his final results.
The importance of data cleaning was emphasized to
an even greater extent in Benjamin Neale’s presentation
of the ‘Quantitative analysis of ADHD from the IMAGE
genome-wide association study’. After using Perlagen
arrays to genotype trios, 27 individuals were excluded
from the study on the basis of low call rates (< 0.87),
gender discrepancies, sample heterozygosity and Men-
delian inconsistencies, with 1865 parents and 936
children remaining. SNP exclusion was dependent upon
allele frequency – with more stringent criteria applied
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to those of low MAF – and eliminated 144,511 (25%)
SNPs from further analyses. Both TDT analysis in
PLINK, and comparison of X2 for high and low p-value
SNPs, revealed a systematic bias in rare and common
allele overtransmission between those SNPs of high and
low (< 0.3) MAFs. Strict Lambda correction was applied
to compensate for the error present in the higher MAF
SNPs – which Neale postulated may have remained
after the less stringent initial quality control. Neale
expects few detectable effects in his data, and is
therefore of the strong opinion that, although a degree
of power may be lost, strict quality control is wise. Just
as in Daly’s first-pass results, no SNPs reached genome-
wide significance, however Neale views this as simply ‘a
state of mind’, with replication proving the true test for
associations.
In an attempt to identify true associations within the
mass of data generated, Neale’s group then supplemen-
ted their p-values with functional landmark information
and re-ranked their SNPs based on these biologically
weighted scores. Replication studies involving thou-
sands of subjects are already planned – however it is
becoming apparent that far larger samples will be
needed in the future – and Neale seemed adamant that
aggressive data sharing and collaboration were the only
answers. Indeed, the data from all of the studies
discussed in this session – and many others at the
conference as a whole – will be made publicly available.
Neale also intends to incorporate haplotype information
into this investigation, using HapMap-based imputed
genotypes, which should go some way to increasing its
power.
In her ‘CHOP ADHD cohort GWA study’, Josephine
Elia is currently in the process of genotyping 500 trios on
the Illumina HumanHap 550 beadchip platform. Again,
no SNPs have reached genome-wide significance, how-
ever Elia’s group have focused upon SNPs found inside
or within 5Kb up- or downstream of previously reported
ADHD candidate genes. So far, several of these SNPs
have been suggestive of association – including DAT 1
and SNAP-25 – however only the association of
ADRA1A remained significant at p¼0.05 with no
apparent parent of origin effects. The treatment of
candidate genes was the focus of some discussion, with
Stephen J Glatt proposing that in GWA research
perhaps one might be more lenient with the p-values of
previously identified candidate genes considering the
prior evidence we have for association, however Daly felt
that there are very few candidate genes worthy of such
leniency. Neale was of the opinion that a blind look at the
genome is the best approach, but added that meta-
analyses incorporating all of the data generated on a
phenotype should continue. Genotyping of Elia’s sample
is still underway and she hopes to recruit more subjects.
The group has also planned longitudinal analyses to
assess genotypic effect on the phenotypic patterns her
group has observed, which suggest that ADHD contains
various clusters of phenotype, which vary with age.
Maja Bucan discussed ‘Novel computational biology
approaches for the analysis of high-density SNP
genotype data’. With an initial focus upon endopheno-
types within the mouse, Bucan’s group identified
potential candidate genes. They then employed a
bioinformatics approach to compile a list of 3000 genes
acting in the synapse and pre-synaptic neuron. The
group also searched for extremely large conserved non-
coding elements across different species. Examination of
the regions has begun, and Bucan called for more model
organism work and better annotation of the genome.
The next step would be to concentrate on those SNPs and
CNVs falling within and near these candidate genes and
conserved elements during the group’s analysis of
genome-wide association data from the entire AGRE
sample, however, only 188 families have been genotyped
on the Illumina Human HapMap 550 beadchips so far.
Again, genome-wide significance has not been reached,
although this is to be expected with the sample size as it
stands.
The group has also developed and tested a novel CNV
detection algorithm – PennCV. PennCV outputs a com-
prehensive report for each gene – as opposed to simply
for each individual – so that one can assess the sizes,
frequency and parent of origin affects of CNVs within
any one gene. In the 2500 individuals the group
assessed, 61,000 CNVs were found, with an extremely
uneven spread throughout the subjects. 846 common
(>1% of the sample) CNVs were identified, and 336 de
novo CNVs were detected in children with autism, some
of which fell within previously reported candidate genes.
Again, the final results were not yet available. However
Bucan’s talk, along with the other three in this session,
does hold promise for the identification of some of the
SNPs and CNVs influencing Autism and ADHD. More-
over, the methods developed and discussed by the
speakers here, from genotyping platforms to novel
research approaches to analytical algorithms, may be
used to enhance the study of many complex phenotypes.
Reference
Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin
C, Walsh T, Yamrom B, Yoon S, Krasnitz A, Kendall J,
Leotta A, Pai D, Zhang R, Lee YH, Hicks J, Spence SJ,
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Warburton D, King MC, Skuse D, Geschwind DH,
Gilliam TC, Ye K & Wigler M. 2007. Strong association
of de novo copy number mutations with autism. Science
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3. GENOME-WIDE ASSOCIATION STUDIES OF
DEPRESSION, PANIC DISORDER AND
ANTIDEPRESSANT TREATMENT RESPONSE
Reported by Melanie Carless
Depression is symptomatically characterized by altera-
tions in cognitive, psychomotor and emotional processes
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(Lesch, 2004). The clinical features, severity and course
of the illness are highly heterogenous within patients
and the genetic basis of depression is highly complex,
polygenic and epistatic (Lesch, 2004). Anxiety disorders,
including panic disorder, display common symptoms
with depression with approximately 60% of depressed
patients also experiencing anxiety symptoms (Baldwin
et al., 2002). Pharmacological agents used for depression
include enzyme inhibitors, uptake blockers and receptor
blockers; with selective serotonin reuptake inhibitors
(SSRIs) being the most widely prescribed drug for mood
and anxiety disorders (Artigas et al., 2002; Golden,
2003). The complexity of mood and anxiety disorders has
made the identification of susceptibility genes difficult.
In the past, candidate gene analyses and linkage studies
have had limited success in consistently identifying
susceptibility genes contributing to for example, major
depression. The current classification scheme, which is
based on clusters of symptoms rather than describing a
homogenous disorder, is likely to contribute to this
(Hasler et al., 2004). Genome-wide association studies
(GWAS) have been successfully employed to identify
genetic regions associated with a number of diseases
(WTCCC, 2007) and may also provide a sound bench
mark for the delineation of regions involved in depres-
sion and panic disorder.
The GWAS of mood and anxiety disorder session
opened with presentations by Drs Patrick Sullivan and
Steven Hamilton examining GWAS of major depressive
disorder (MDD). Dr Sullivan is currently performing a
large scale GWAS using 1,860 patients with MDD in the
Netherlands Study of Depression and Anxiety (NESDA)
cohort and an equal number of controls obtained from
the Netherlands Twin Registry (NTR). His aim was to
perform a two-stage study, initially to examine 430,000
SNPs using a Perlegen single nucleotide polymorphism
(SNP) array and to then replicate the most promising
15,000 SNPs, further refining this to a second replica-
tion of 20 SNPs. Although no results were presented,
these studies are underway and the identification of
genetic variations associated with MDD susceptibility
are promising.
Dr Hamilton presented preliminary data on the
Sequenced Treatment Alternatives to Relieve Depres-
sion (STAR*D) cohort consisting of a diverse collection of
white non-Hispanics (n¼ 1,279), African Americans
(n¼ 313) and white Hispanics (n¼ 247) individuals
across the United States. For this study, a subset of
633 white non-Hispanic cases from the STAR*D cohort
were collected through a clinical trial examining drug
response and were genotyped using the Affymetrix 500K
mapping array and 5.0 array platforms. Also, 879
independent controls from the National Institute of
Mental Health (NIMH) had been previously genotyped
using an Affymetrix platform for this study. In this
preliminary analysis, seven SNPs were identified as
possibly being associated. However, as there were no
other SNPs in the surrounding areas that were
significant, it was suggested that these may be false
positive results. Dr Hamilton commented on the fact
that findings need to be replicated, both in a larger
STAR*D cohort and also in an independent population.
The next two presentations, delivered by Dr Brian
DeChairo and Mr Jeffrey Kraft, pertained to patient
response data following the administration of SSRIs. Dr
DeChairo presented a meta-analysis of eight different
pharmacological response studies investigating the
administration of Sertraline (n¼1), Fluoxetine (n¼ 2)
and Paroxetine (n¼5). Across the eight studies 477
individuals were administered a SSRI and 451 indivi-
duals were administered a placebo and all samples were
genotyped using the Perlegen SNP array platform. Dr
DeChairos’ approach was to analyze responders admi-
nistered an SSRIs (endpoint) and to compare this to
responders administered a placebo to determine the
‘‘placebo effect’’. After replication in two populations two
SNPs, rs1324058 and rs17670808, were significantly
associated with SSRI response. Dr DeChairo further
concluded that data from smaller populations should be
merged prior to analysis as significant results obtained
from small populations are unlikely to replicate in
another population due to their lack of statistical power
in both studies.
Mr Kraft investigated both response and remittance
(as endpoints) in the STAR*D cohort and found a
number of genetic variants to be significantly associated
with each of the SSRI endpoints, many of which
overlapped (> 50% of response associated SNPs were
also remittance associated SNPs). Mr Kraft investigated
1,279 individuals (53% non-responders, 14% respon-
ders, 33% remitters) using the Affymetrix 500K map-
ping array and 5.0 array platforms. Using a statistical
significance threshold of p< 1104, five SNP clusters
(1p34.3, 8q11.23, 9p21.1-21.2, 19q13.12, 21q21.3) were
associated with the remittance phenotype. The 1p34.3
and 9p21.1-21.2 SNP clusters were also associated with
the responder phenotype, as were some other individual
SNPs.
The final presentation of the session, delivered by Dr
Angelika Erhardt, outlined a preliminary GWAS of
anxiety disorders (80% panic disorder) using the
Illumina 300K BeadChip. Employing a two stage study
design, this German study genotyped 216 cases and 222
controls in stage one and an independent ascertainment
of 236 cases and 241 controls in stage two. Of the five
genes (KPNA4, FHIT, CRIM1, PLCB1and TMEM132D)
exhibiting suggestive significance across both study
stages, Dr Erhardt reported the hypothetical protein
TMEM132D to satisfy genome-wide correction factors in
both populations. Although results were preliminary,
the analysis is promising and further studies are
underway to investigate expression differences in
animal models of pathological anxiety.
One of the major points to arise during this session
and subsequent discussion was the need for a collabora-
tive effort. In particular, Dr Sullivan commented on the
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formation of a Psychiatric GWAS Consortium originat-
ing in May 2007, and how it is now developing into a
powerful tool for the detection of genetic variation
associated with various psychiatric disorders. Currently
funded by NARSAD, the consortium aims to draw upon
approximately 30 research cohorts with a total of
approximately 50,000 individuals (31,000 cases and
19,000 controls). Of the five different disorders to
be studied (attention deficit-hyperactivity disorder,
autism, bipolar disorder, major depression and schizo-
phrenia), major depression cases will contribute largely
to the study with about 8,000 cases and 8,000 controls. It
is encouraging to note that all research groups that have
been approached about the consortium have had a
positive reaction, indicating a shared ideology for
collaborations to increase the power of GWAS.
One of the major concerns raised during this GWAS
session was the extent of heterogeneity across studies, an
issue that is likely to become much more prominent with
the development of a consortium. The discussion mod-
erator, Dr Michael Gill, commented that phenotypic
definition needs to be consistent across studies with a
subsequent response from Dr Hamilton that each study
does employ a subjective means of diagnosis and
selection; hence it would be difficult to eliminate
heterogeneity. This opinion was echoed throughout the
discussion by each of the speakers with the consensus
that population heterogeneity does exist and that it may
cause problems in studies of this magnitude. Dr Gill
questioned whether this problem can be fixed, however
no formal solution was voiced during this session.
Diagnostic heterogeneity is therefore an important issue
to consider during study design, analysis and result
interpretation as the advent of false negative results and
an inability to replicate results is highly likely.
Phenotypic classification is not only a heterogeneity
issue but it can also shroud the extent of information
obtained from a study. The possibility of a ‘‘pheno-wide’’
study was opened for discussion, specifically whether
phenotypic variants could also be associated with
specific genetic variants. Dr DeChairo commented that
we could look for association by narrowing the pheno-
type, but that we could also broaden the phenotype. Dr
DeChairo also questioned the subjectivity of diagnosing
psychiatric disorders and whether single or multiple
phenotypes will be consistently diagnosed. The question
of whether drug tolerability can be considered as a
phenotype was also posed. Dr Hamilton responded by
suggesting that we may be able to identify markers that
are predictive of a clinical endpoint as well as those that
define genes and genetic pathways associated with
psychiatric diseases.
Another important issue that was raised was a lack of
stage two design and the question of ‘‘where we go from
here’’ remains. In response, replication studies were
proposed to confirm the ‘‘top hits’’ (i.e. the top 2,500–
50,000 SNPs). However, this response was debated in
that it would be financially ineffective to examine 50,000
SNPs as part of a replication and/or second stage of a
study. Meta-analyses were also suggested to potentially
provide more insightful information and that perhaps
the best way to determine if a particular genetic variant
is significantly associated with any psychiatric dis-
order is to combine genotypic information from many
studies. Dr Gill also raised a concern that if we fail to find
something in these smaller populations, this may affect
our ability to get funding for larger studies.
To date, meta-analyses reported from The Wellcome
Trust Case Control Consortium (WTCCC) have identi-
fied a number of novel genetic regions associated with
various non-psychiatric disorders such as coronary
artery disease (9p21.3), Crohn’s disease (3p21, 5q33,
10q24, 18p11), rheumatoid arthritis (7q32, in females
only), type 1 diabetes (12q13, 12q24, 16p13) and type 2
diabetes (6p22, 16q12) (2007). A number of candidate
genes reside in these genetic regions, although these
have not been functionally verified in the diseases.
However, this proof of concept gives promise to the
future of the Psychiatric GWAS Consortium and the
identification of genes associated with psychiatric ill-
ness, including major depression and panic disorder. We
may still have a long way to go in the identification of
genes and genetic pathways involved in psychiatric
diseases but the data presented during this symposium,
along with the discussion and future collaborative
efforts generated promises to advance our knowledge
of the genetics underpinning psychiatric disorders.
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4. STATISTICAL METHODS FOR
GENOME-WIDE ASSOCIATION STUDIES
Reported by Robert Karlsson
Four presentations describing new statistical methods
related to genome-wide association studies were given
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by Goncalo Abecasis, Shaun Purcell, Itsik Pe’er, and
Frank Dudbridge.
Goncalo Abecasis: Turning a flood of data into a deluge:
‘‘in silico’’ genotyping for genome-wide association scans.
Dr. Abecasis discussed the rationale for ‘in silico
genotyping’, and methods to perform it. His message
was that we can produce quite dense SNP genotypes
today, but it would be even better to have even denser
genotypes, in order to pinpoint disease loci more
precisely. Furthermore, for maximum power in GWAS,
we would like to have as large sample sizes as possible.
Manufacturing denser SNP chips and collecting more
individuals is very expensive, but we can get further
information from the data we have today by imputing
genotypes with in silico methods.
Two approaches were suggested: Increase genotype
density in related individuals, where most are geno-
typed only on a few markers, by following the segrega-
tion of these markers through the pedigree to determine
where recombinations happen, and then filling in the
missing markers from chromosome segments shared
with more densely genotyped relatives. Alternatively
increase genotype density in unrelated (actually dis-
tantly related due to population history) individuals
by the same principle, but using e.g. Hapmap data
(which is genotyped at about 2.5 million SNPs) to ‘fill
in the blanks’. A maximum-likelihood estimate was
used for each genotype imputation. This method has
been tested on various datasets, and found to be
more powerful than analyzing the data using other
approaches. The algorithm can also use the combined
Hapmap data (all groups) to make decent genotype
imputations.
Among the several questions posed, Dr. Abecasis was
asked whether this new software will be available on his
website, and if guides and tutorials for performing the
analysis will be provided, as has been made for his other
software packages. He replied that this will happen
soon, but did not give an exact time frame. Another
question was on how long the analysis takes to perform.
Abecasis’ reply was that currently on an ordinary PC
the imputation takes about one day per chromosome.
Another audience member asked how robust this
method is to genotyping errors. To this Dr. Abecasis
replied that, as always, if you don’t do a decent quality
control on your data, you cannot trust your results. With
that in mind, the results after imputing genotypes
do not get any worse than before imputation on data
with genotyping errors. The last question for Dr.
Abecasis was whether his method really is different
from a (much simpler to compute) multiple regression
based on known genotypes and their correlation with
unknown genotypes. His reply to this was that it is
different, because the MLE approach takes into account
the local (non-linear) LD block structure of the
genome, which is not processed accurately by a multiple
regression.
Shaun Purcell: An examination of rare variation and
extended segmental sharing in whole genome studies of
bipolar disorder and schizophrenia. Dr. Purcell pre-
sented his progress in the development of a method for
finding relatively recent and rare population-specific
mutations associated with bipolar disorder and schizo-
phrenia. His reasoning motivating this was that recent
mutations that have spread in a population should come
with a long haplotype region of linkage disequilibrium
surrounding it, since it has not yet had time to break
down from recombinations. This uncommonly long
stretch of markers is shared among individuals with
the disease caused by the mutation, and thus an
association between haplotype and disease that is
detectable by Purcell’s algorithm emerges. Importantly,
applied to the same whole genome SNP datasets
currently being collected and analyzed with common
variation in mind, this method aims to provide a
complementary way to scan for rarer but more pene-
trant variants that would otherwise be missed.
Dr. Purcell suggested an algorithm based on a Hidden
Markov Model to detect long haplotypes that are shared
both between chromosomes in the same individual
(extended stretches of homozygosity) and between
distantly related individuals. The latter method can be
seen as a sort of population-based linkage analysis.
Restrictions on the length of haplotypes are set to limit
the analysis to fairly recent mutations, which approxi-
mately corresponds to haplotypes of over 1 Mb of length.
An important caveat when using this method is that
different rates of relatedness in case and control groups
due to sampling bias can have a huge influence on the
outcome. Therefore extra care should be taken to avoid
such bias.
The algorithm is implemented in Purcell’s PLINK
software package (Purcell et al., 2007), which is freely
available on his website http://pngu.mgh.harvard.edu/
purcell/plink/. Dr. Purcell has tested his method on
two real world datasets: genotypes from the bipolar
patients in the STEP-BD study, and a subset of the
WGAS genotypes from the International Schizophrenia
Consortium. Results are still being interpreted and
validated, but a few regions turned up as potentially
interesting for haplotype sharing.
Itsik Pe’er: Genetic analysis of GWA data in an admixed
population. Dr. Pe’er’s presentation addressed the
problem of admixed populations in whole genome
association studies. WGAS are known to have the
highest power if the sampled population has a homo-
geneous ancestry, but most often that is not the case.
The problem with samples from admixed populations is
that if the admixture is not taken into account during
association analyses, p-values in an association study
can be greatly inflated due to this admixture, rather
than true disease association. Pe’er’s software (Xplor-
igin) addresses this problem. Xplorigin is available (with
Cþþ source code) from http://www.cs.columbia.edu/
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itsik/Xplorigin/Xplorigin.htm. Pe’er demonstrated his
methods to be superior to the popular ‘‘Genomic Control’’
approach. On simulated data without a disease effect he
compared them by quantile-quantile plots to an uncor-
rected association study (proportion of low p-values
highly inflated), Genomic Control (better, but over-
correction leads to a deficiency of low p-values), and
Principal Component Analysis (better still, but a small
tendency towards overcorrection). Pe’er’s methods
called Ancestry Proportions (the most accurate-looking
plot) and ‘‘Local ancestry’’ (similar to the PCA and
Ancestry Proportions plots, but with a small tendency
towards too low p-values) looked the most promising.
The power of local ancestry and ancestry proportions
analyses was also demonstrated in a simulation where a
disease effect was present, and the Xplorigin treated
data gave the clearest signal from the disease locus
(again compared to Genomic Control and PCA).
One question posed was whether Pe’er had any
suggestion on how to handle population-based samples
from the USA, where 10–15% of the population has
African American ancestry. Pe’er’s answer to this was
that it is important to never throw away data, but we
have to be very careful when we analyze it. We might not
be able to perform the ’correct’ analysis today, but
development is ongoing in the area, so we should keep
our data in anticipation of better analysis methods.
Frank Dudbridge: Estimating significance thresholds
for genome-wide association scans. Dr. Dudbridge
gave a presentation on how to determine the p-value
threshold for significance in genome-wide association
studies, something which is far from trivial due to
among other things linkage disequilibrium between
nearby markers on SNP chips, which makes Bonferroni
correction inappropriate, and the fact that we don’t
know how many ‘true positive’ findings to expect in a
GWAS.
Using permutations of data from the WTCCC blood
donor control group, where half of the group randomly
was assigned a ‘case’ status, Dudbridge could find a good
approximation of the null distribution of minimum p-
values. This was repeated for subsets of SNPs with
varying density, and for each density the 5% quantile of
minimum p-values was calculated.
Extrapolating this to an infinitely dense marker map
by fitting the monod curve to the effective number of
tests, Dudbridge found a p-value threshold of 6.0 108
to be appropriate for genome-wide significance. Since
this threshold assumes an infinitely dense marker map,
it should apply regardless of which panel a specific study
uses. Dudbridge’s suggested threshold is an order of
magnitude smaller than that used in the WTCCC
studies. However, of the 11 reported significant results
from WTCCC:s studies, only 1 had a p-value in the
critical interval (6 108, 5107), so using the thresh-
old suggested by Dudbridge would not have made a big
difference for the overall outcome of that specific study.
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5. BRAIN IMAGING IN GENETIC
ASSOCIATION STUDIES
Reported by Aristotle N. Voineskos
Brain imaging and genetics are two powerful lines of
neuroscientific enquiry that when combined may be able
to provide better answers than either technology alone.
Though a statistical relationship between a risk allele
and a clinical diagnosis may not be shown, there may be
a significant effect of that allele on a biological process
for the illness that can be demonstrated using brain
imaging. However, the issues of multiple testing, small
sample size, and spurious associations faced in both
genetics and imaging can prove challenging in study
design and analysis.
This report highlights various approaches and limita-
tions of combining imaging and genetics by summariz-
ing five presentations and the subsequent discussion in
the symposium.
Presentation 1: Genome Wide Association Study of PET
Scan Phenotypes (Dr. Xinmin Liu, NIH). This first study
examined potential positron emission tomography
(PET) imaging endophenotypes in mood disorders.
These were defined as binding potential (BP) of [11C]
DASB PET, a ligand for the serotonin transporter
and [18F] TZTTP, a muscarinic receptor ligand. This is
the first genome-wide association study examining
positron emission tomography (PET) imaging endophe-
notypes in mood disorders. These phenotypes were
defined as binding potential (BP) of [11C] DASB, a
ligand for the serotonin transporter and [18F] TZTTP,
a muscarinic receptor ligand in the PET. 144 unmedi-
cated individuals underwent scanning with one or both
of the above ligands. DNA samples were genotyped
with 109,365 single nucleotide polymorphisms (SNPs)
by use of the Illumina Infinium I chip. Genetic associa-
tion testing with BP at either receptor was carried
out by logistic regression controlled for ethnicity.
Correction for multiple testing was made using the
false discovery rate (FDR). For residual bias detection, a
QQ plot was constructed and no residual bias was
detected.
For the muscarinic receptor binding phenotype, the
rs1519781 SNP was associated with [18F] TZTTP BP in
a conserved region on chromosome 2q23.3 (p¼6.92
108). The SNP rs2279508 near the SLIT1 gene was
associated at p¼ 1.68  106. SLIT1 encodes a protein
thought to be involved in axonal migration. The im-
plicated genes may play a role in mood disorders.
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Presentation 2: False Discovery in Psychiatric Imaging
Genetics (Dr. Daniel Weinberger, NIH). This study was
designed to determine the false positive rate in imaging
genetics using genotypes (real and permuted) with low
prior probability of association. Seven hundred twenty
common nonconservative SNPs with >10% minor allele
frequency (MAF) that did not show significant associa-
tion with schizophrenia in either family or case control
datasets were chosen. Four hundred ninety two of
these SNPs did not show association with cognitive
measures and these were analyzed separately. For
each SNP the effects on brain structure using voxel
based morphometry (VBM) and fMRI in 126 normal
volunteers with whole brain and ROI approaches
were examined. Phenotypes studied included the N
back and fearful face paradigms using fMRI and
optimized VBM for brain structure. Genotypes were
also permuted destroying the genotype-phenotype rela-
tionship and the analyses repeated. The imaging data
were analyzed in SPM2 with a standard alpha of p¼ 0.05
corrected for both family wise and false discovery error
rates.
For all analyses the rate of positive voxels was well
below 5% (range 0.8–1.4%) and significantly (p< .05,
one sample t test) different from 5% for all comparisons.
There was no relationship between the region of interest
and the false positive rate. Since false positive results
would have been expected in 5% of analyses this study
provided empirical evidence that the type I error rate is
well controlled by commonly used correction procedures
in the imaging genetics paradigms used.
Presentation 3: The BDNF val/met polymorphism and
hippocampal volume in Dutch Schizophrenia Patients
and Controls (Dr. Steven Baker, Utrecht). A study of a
Dutch cohort consisting of 75 schizophrenia patients
(diagnosed according to DSM-IV criteria) and 97 healthy
controls sought to replicate a previous study showing
that the BDNF val66met variant has been found
associated with reduced hippocampal volume in healthy
individuals with more pronounced effect in schizophre-
nia patients. MRI scans were obtained on a 1.5T Philips
scanner. Volumes of the whole brain, intracranium, and
hippocampus were determined. The BDNF val/met
polymorphism was genotyped by allele specific PCR.
The effect of genotype on whole hippocampal volume
corrected for age, gender and intracranium was deter-
mined using UNPHASED software.
In the combined sample (n¼172) genotype was not
associated with hippocampal volume (p¼ .69). In schizo-
phrenia patients (n¼ 75) there was a trend towards
association (p¼ .08) with hippocampal volume. Post hoc
testing did not show allelic association (p¼ .21 in
patients; p¼ .85 in all subjects).
Presentation 4: Gene Discovery through Imaging Genet-
ics: Identification of 2 novel genes for schizophrenia (Dr.
Steven Potkin, University of California Irvine). In this
study the fMRI activation paradigm of left hemispheric
dorsolateral prefrontal cortex activation was used as a
phenotype to identify candidate genes for schizophrenia.
Two novel genes have been identified for schizophrenia
using this method.
The discovery sample (n¼28 patients with chronic
schizophrenia) was genotyped on the Illumina Human1
(109,365 gene-centered SNPs) chip and subjects in the
verification sample (n¼ 173) on the Human Hap300
(317,503 HapMap tagging SNPs). Significant associa-
tions were found on chromosomes 3 and 6 with a circuit
involving Brodmann areas 8 and 46, with p values
estimated at 106. Two genes were identified by having
at least one SNP whose QT (quantitative trait) analysis
was significant at p< 108 with an empirical p value of
106 by permutation. These genes were compared to
uncus and hypothalamus (used as control regions) and
there was no association.
SNPs related to these two genes in an independent
case-control study collected by the FBIRN consortium
(www.nbirn.net) were then tested. Fifteen SNPs in
these genes were significant. Using a novel genome
wide screening strategy with brain activation as the
quantitative phenotype two genes have been dis-
covered and verified. Imaging derived neural pheno-
types are continuous, quantitative, richer than
symptom based diagnoses, and provide considerably
more statistical power reflecting the greater penetrance
of genetic effects at this more biologically more prox-
imate level.
Presentation 5: (Dr. Patrick Sullivan, Duke University).
The Risk of False Positivity. This study in its entirety has
been described elsewhere (Wright et al., 2007; Sullivan,
2007). It had three main goals: 1) discover the risk of
false positives in genetic association studies, 2) under-
stand whether different definitions of replication extin-
guish vs. propagate false positives, and 3) undertake
realistic simulations of a genetic association study using
a typical sample size (500 cases and 500 controls) with
typical candidate genes.
Realistic simulations via HapSample created 1000
association samples consisting of 500 cases and 500
controls. Genotypes were generated for 10 COMT
functional and htSNPs under a null model. All associa-
tion samples were analyzed for a typical suite of
analyses – main effects, main effects stratified by sex,
haplotype analyses using a sliding window and five
endophenotypes available in cases only. Any positive
findings were considered to be false positives by defini-
tion. 96.8% of the studies produced significant findings
at p< .05 with a median of 6 false positives per study. All
positive studies were replicated 10 times. Using a
definition of replication as one in which any one SNP
was positively associated with any one phenotype, all
studies replicated at least 7 times, and 67% replicated
10/10 times.
Therefore, chance can easily generate findings that
seem compelling or intriguing. False positive findings
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can propagate and confuse the literature unless the
definition of replication is precise. For the association
method to function as intended, every statistical com-
parison must be tracked and reported, and precise
replication (the same SNPs, phenotype, and direction of
association) is required.
Discussion
The emerging field of imaging genetics is exciting but
challenging. It is an intersection of 2 fields defined by a
high multiplicity of data. Whole Genome Association
studies use strategies of increasing sample size and
power in relation to small effects.
Several major imaging genetics findings have created
great optimism for an intermediate phenotype strategy
in psychiatric genetics research. There may be ability to
find greater effect on more refined or less complex
phenotypes. However, there are several challenges.
1) Imaging genetics studies that use small samples may
suffer from genetic heterogeneity since different alleles
at the same locus can be associated with disease in
populations of different ethnic composition.
2) In using imaging data in disease populations,
medication effects on brain structure and function must
be considered. Both antipsychotic as well as antidepres-
sant medications can have an effect on brain volume,
particularly gray matter. For instance antidepressants
may affect BDNF expression, and thus would be
important to consider when measuring the effect of the
BDNF gene on hippocampal volume, or the effect of
antipsychotics on gray matter volumes in general and
basal ganglia volume in particular.
3) The selection of statistical correction methods for
multiple comparisons is central to an imaging genetics
study. Currently FDR and family wise error (FWE) rates
are often used. Presentation 2 effectively showed that
these methods are adequate for certain types of imaging
genetics studies. Bonferonni correction is perhaps the
simplest and safest approach for genetics studies
involving many tests, as suggested in presentation 5.
However, it is the most conservative approach, and may
be overly conservative, since SNPs within genes are not
necessarily independent, and neither are voxels or
certain brain regions. Another alternative is to use a
Monte Carlo method. This approach is well defined in
both genetics (Martin and Kaplan, 2000) and imaging
(Nichols and Holmes, 2002).
4) Almost implicit in point number 3, is that of the
challenge of replication. Indeed, the ‘Winner’s Curse’
has been well documented in genetics studies of complex
disorders (Goring et al., 2001). Ensuring rigorous
statistical correction approaches, allows the scientific
community at large more certainty in both the original
study and attempts at replication. In depth suggestions
on what constitutes replication of a genotype-phenotype
association and how it can be best achieved have
recently been published (Chanock et al., 2007). Further-
more, calculating pre-study odds may help improve our
understanding of a positive finding (Ioannidis, 2005).
5) The challenge of undertaking a metanalysis was
raised. Such an approach is useful in pooling various
small studies to increase sample size and examine
effect. However, there are many potential confounds to
consider in imaging genetics, perhaps more so in
imaging. Studies at different centers use different
scanners, with different field strengths. Even scanners
made by the same company at the same field strength
display considerable variability (Littmann et al., 2006).
Different software, and different approaches (VBM vs.
ROI) methods are used by different centers. It is a great
challenge to find a way to combine existing data in a
metanalysis.
On the whole, brain imaging is an excellent tool to
provide a more objective phenotype, as well as function
as an intermediate phenotype ‘closer’ to the effects of the
gene. It provides an opportunity to both discover at risk
neural networks in disease, and identify genes that may
not show effect at the level of a complex behavioral
disorder.
Studies conducted in each discipline, but particularly
genetics carry the risk of spurious associations or false
positives, that often do not stand the test of replication.
The combination of imaging and genetics may lead to
more tests requiring correction, but overall the advan-
tages and the biological face validity of using imaging
phenotypes in genetics should help accelerate progress
in this field.
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6. ENDOPHENOTYPES IN SCHIZOPHRENIA
AND BIPOLAR DISORDER
Reported by Elizabeth Hare
Psychiatric illnesses have been difficult to characterize
genetically due to their clinical and genetic heterogene-
ity and the complex interplay of genetic and environ-
mental factors that produce their phenotypes. The
analysis of endophenotypes is an approach that provides
an alternative method of understanding the genetic
basis of these disorders. The essential features of
endophenotypes were defined by Gottesman and Gould
(2003) as: association with the illness, heritability
demonstrated by increased risk for the endophenotype
in healthy relatives, state-independence (manifestation
whether illness is present or not), and cosegregation
with the disease within families. An additional sug-
gested criterion is that the endophenotype is present in
family members of individuals with the illness at a
higher rate than in the general population.
Dr. Raquel Gur was the Chairperson of the Oral
Session on Endophenotypes at the XV World Congress
on Psychiatric Genetics. Presentations were given by
Drs. Maartje Aukes, Dan Rujescu, Clyde Francks and
Michel Maziade. The discussion following these pre-
sentations was moderated by Dr. Michael Owen.
The first presentation was by Aukes, who discussed
the identification of two useful endophenotypes in the
study of schizophrenia: openness and sensorimotor
gating. In this study, a battery of neuropsychological
and psychophysiological tests was administered to 180
subjects from 25 multigenerational families with multi-
ple members affected by schizophrenia. Statistical
analyses included familial correlation for the selection
of heritable traits, heritability estimation, and segrega-
tion analysis. Moderate familial correlations were found
for sensorimotor gating measured with prepulse
inhibition, openness, verbal fluency, early visual per-
ception measured with backward masking, and spatial
span, with heritabilities estimated from 0.37 to 0.54.
Sensorimotor gating and openness were found to have
an inheritance pattern similar to a major gene model
with a dominant mode of inheritance, and it was
suggested that the other traits were probably the result
of more complex modes of inheritance.
Dr Rujescu described a wide range of studies includ-
ing a scan for association with schizophrenia and
cognitive endophenotypes, and gene expression studies.
The association study focused on gene regions known to
be linked to schizophrenia and candidate genes. The
FOXJ1 gene was found to be weakly associated with
schizophrenia and executive function, and FOXP1 was
associated with memory. The Plexin B3 receptor,
another candidate, is a protein that is expressed in the
white matter and is involved with neurite outgrowth in
axons. It is associated with brain volume, which is highly
heritable, and is involved with cognitive function but
not schizophrenia. A mouse model was described in
which disruption of the crystallin CRYBB2 gene lead to
altered prepulse inhibition and behavioral alterations.
Genetic variations in this gene were associated with
cognitive endophenotypes and saccade eye movements
in humans.
Dr Francks described findings of a gene, LRRTM1
(Leucine-rich repeat transmembrane neuronal 1), asso-
ciated paternally with handedness and schizophrenia.
Left-right asymmetrical brain function has been impli-
cated in the development of schizophrenia as well as
handedness. This work utilized methods including
association mapping, analysis of imprinted expression,
Northern blotting, methylation analysis and subcellular
localization. Association was found between LRRTM1
and a quantitative measure of handedness in siblings
with dyslexia when the haplotype of interest is inherited
paternally. The same haplotype was found to be
overtransmitted paternally to individuals with schizo-
phrenia. By examining the patterns of expression of
LRRTM1 in forebrain development, Dr. Francks and his
colleagues determined that the protein could influence
neuronal differentiation and connectivity. The endo-
phenotype of handedness may be related to schizo-
phrenia and dyslexia and may provide insight into
neurodevelopment.
Dr Francks presented evidence for a signal of positive
selection upstream of LRRTM1 in the European-descent
population, based on analysis of Hapmap data. A
member of the audience pointed out that this signal
was found only in the European population, and not in
the African or Asian populations. He asked if the correct
interpretation was that only in the European descent
population was it an evolutionary advantage to be right-
handed. Dr Francks responded that that the situation
was complex and that possibly a new haplotype had
arisen in the European population that was protective
from psychosis when associated with abnormal brain
asymmetry.
The concern was raised by another audience member
about whether handedness should be considered an
endophenotype for schizophrenia. Was the underlying
assumption of this study that there is a single gene for
handedness that is related to schizophrenia, or as Dr.
Francks suggested, there is more than one gene for
handedness, and that the one he focused on was just one
of them. There was also mention that paternal transmis-
sion of handedness, as suggested by Dr. Francks, was in
question, and that large studies of handedness in the
population fail to show this. Dr. Francks commented
that if multiple genes were involved, others that were
not paternally transmitted, it is unlikely that paternal
transmission would be detected in epidemiological
studies.
The next speaker, Dr. Maziade, described the use of a
standard neuropsychological battery with 45 offspring
of families affected with schizophrenia or bipolar
disorder who were at high risk of developing these
conditions themselves. These subjects had at least one
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parent with either schizophrenia or bipolar disorder,
and were individually paired with age- and sex-matched
controls. High risk offspring showed significant differ-
ences from controls in memory and some areas of
executive functioning (initiation and planning). Moder-
ate to large effect sizes for IQ and memory were higher
than those reported in the literature. It was suggested
that there are similarities between the deficits of
individuals at risk for schizophrenia and bipolar
disorder, and that the differences are mostly in the
magnitudes of the impairments rather than the types of
impairments found. These effects remained the same
when subjects were divided into two age categories,
suggesting that these are prodromal traits. It was also
suggested that in individuals with particularly high
genetic loading for these disorders, the impairment was
greater than in a more general high-risk population
and that this represents a dose-response relationship
between genetic risk loading and level of impairment.
There was a question from the audience regarding
some findings in the literature that those at risk for
bipolar disorder have similar or better cognitive abilities
when compared with controls. Dr. Maziade reiterated
that while there were many more studies in families
with a high risk of schizophrenia then in families with a
high risk of bipolar disorder, they showed a similar
profile of impairment with the schizophrenic population
having worse performance on cognitive tests than the
bipolar population.
The panel discussion following the presentations had
a broad focus on the appropriateness of the use of
endophenotypes to elucidate the genetic factors in
psychiatric conditions. The moderator expressed a need
for caution in planning and interpreting studies invol-
ving endophenotypes, stating that these studies rest on
the assumption that the endophenotype is caused by
something that lies on the disease pathway. This is not
particularly problematic when endophenotypes are
used to find genes; however, when they are used to
study the function of genes and how genes lead to
disease, it can be misleading. Such associations are
difficult, if not impossible, to prove or disprove and the
phenomenon of pleiotropy makes it difficult to sort out
whether a gene is on the disease pathway or has effects
on two (or more) unrelated traits.
In response to these words of caution, several
individuals raised the issue of the complexity of a
disorder like schizophrenia with its clinical and genetic
heterogeneity and the difficulties and controversies
about the definition of the disorder. The lack of
significant findings for many genome-wide association
studies was mentioned as another reason that multiple
methods are needed to disentangle the genetic complex-
ity of these disorders. A researcher from Finland
suggested using meta-analysis of datasets from differ-
ent countries. An audience member asked whether it
would be possible to use the same core battery of
neurocognitive tests world-wide so that meta-analyses
could be performed. Another person answered that the
same tests are used for most of these studies.
It was suggested that the traits chosen as endophe-
notypes may be too complex, particularly the results of
neurocognitive testing. Some of this testing requires
complicated chains of thought and behavior, and it
might be more effective to choose simpler traits such as
evoked responses measured with EEG. Other sugges-
tions were that psychiatric geneticists work closely with
researchers developing animal models to ensure the
ability to study detailed aspects of behavior, that the use
of medication is taken into account when analyzing
neurocognitive data, and that factor analysis could
be used with scales of symptoms to produce useful
endophenotypes.
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7. GENETICS OF MOOD DISORDERS
Reported by Deepak Grover and Ranjana Verma
The first speaker in this session was Dr. Sven Cichon
from The Life & Brain Center, University of Bonn and
title of his talk was ‘‘Genetic variation in the gene
for brain-expressed tryptophan hydroxylase 2
(TPH2) is associated with bipolar affective dis-
order’’. Dr. Cichon highlighted the biochemical func-
tion of tryptophan hydroxylase in 5-HT synthesis. 5-HT
is involved in a broad range of behavioral functions
known to be disturbed in affective disorders, e.g. mood
control, sleep, sexual behavior, drug abuse, food intake.
Also, low levels of 5-HT are found in patients with
depression, suicide victims. The synthesis of 5-HT in
brain is controlled by a TPH2 isoform of the gene which
is present on chromosome 12 (Walther et al., 2003). The
study he carried out was aimed to access the possible
contribution of the TPH2 gene in the development of
bipolar disorder. The strategy involved resequencing of
the coding region of this gene that consists of 11 exons, in
897 bipolar patients and 1335 controls. The sample set
comprised of two cohorts, a German sample (649 cases
and 1105 controls) and Russian sample (248 cases and
231 controls). The results revealed a haplotype block in
the 50 region of the gene, and a rare coding non-
synonymous SNP rs11178997, significantly associated
with the disease. The odds ratio for the haplotype block
association was 1.5 and that for the associated SNP was
5.2. The SNP rs11178997 was observed in family history
positive patients with BPAD, and evidence for co-
segregation with affective disorder was observed in 3
families. The SNP accounts for an amino acid change
from hydrophobic proline to polar serine. Homology
based prediction suggests the occurrence of this amino
acid Pro206 in a highly conserved structural domain of
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the protein. Functional studies demonstrate that this
polymorphism leads to reduced solubility and thermal
stability, but no significant change in catalytic activity of
the enzyme. Another recent study implicates the same
promoter polymorphism in reduced TPH2 activity in
seretonergic neurons (Scheuch et al., 2007). The speaker
concluded by suggesting reduced 5-HT production in
brain as a pathophysiological mechanism of Bipolar
disorder. He also stressed the need to investigate both
common and rare variations, as the SNP rs11178997
that was detected by resequencing, could have escaped
detection based on Hapmap data.
Dr. Randy Blakely from Vanderbilt University School
of medicine was the second speaker of the session. His
talk was entitled Good riddance to serotonin: molecular
regulation and genetics of serotonin transporters. He
highlighted that serotonin transporter (SERT) is the
focus of study in the etiology of many mood disorders. It
has also been investigated in the course of pharmacoge-
netic studies as there is evidence that drugs including
antidepressants (cocaine and amphetamines) impact
SERT activity. His strategy involved identification of
structural domains in SERT that lead to neurotrans-
mitter and antagonist specificity using site directed
mutagenesis and molecular modeling. They are using
site specific antibodies and electrophysiological techni-
ques to evaluate the post-translational mechanism
involved in acute carrier regulation in vivo and in vitro.
They are also using transgenic mouse models to study
the biochemical and behavioral consequences of SERT
defects in humans. Their group has identified sites, that
when mutated, lead to loss of SSRI and cocaine
recognition by the transporter without disrupting its
activity. This further lead to the production of a
transgenic mice model that was insensitive to these
agents in vivo. Through gene regulation studies, they
identified two receptors that are linked to protein kinase
G and MAP kinase that fine tune the amount of SERT
available for 5-HT clearance (Zhu et al., 2007). They
believe that these may serve as novel therapeutic
agents. They further carried out molecular genetics
investigations to demonstrate that there exist multiple
coding SNP variants in SERT that account for regula-
tion of gene activity through these pathways.
Dr. Blakely concluded his talk by summarizing the
development of a novel set of tools and targets by their
group that will be useful in the understanding of
involvement of SERT in neuropsychiatric disorders.
He also added that additional identified targets may
lead to development of medication to treat 5-HT
mediated disorders.
Dr. David C. Glahn from University of Texas Health
Science Center made the next presentation entitled
Localization of a Quantitative Trait Locus Influencing
Serum BDNF Levels in an Isolated Nepalese Population.
He mentioned the neurotrophin hypothesis of affective
disorders and other evidence that implicate brain-
derived neurotrophic factor (BDNF) in affective illness
(Martinowich and others 2007). He mentioned that
serum BDNF levels are reduced in people suffering from
major depression, and the levels seem to increase with
the use of anti-depressants. He projected that serum
BDNF levels can serve as an important biomarker for
many psychiatric illnesses, especially major depression.
Their group performed the first family based analysis of
genetic determinants of BDNF levels. They used a single
large pedigree, consisting of 1070 individuals, of the
isolated Jirel population of Eastern Nepal for this
investigation. All these individuals were previously
genotyped for a 10cM genome-wide scan. The variance
component analysis of the genotype data revealed that
serum heritability of BDNF levels was 0.5600.047
(p¼6.7 1045). Genome-wide quantitative-trait link-
age analysis was performed, that localized a single QTL
to chromosome 17p11 region with LOD score of 3.07 with
a nominal p-value 8.5 105 and genome-wide p-value
0.028. They searched for positional candidates in the
linkage region by analysis of transcriptional profiles
(Goring et al., 2007) of a database of Mexican American
individuals for which serum BDNF levels were pre-
viously measured. In the 3Mb linkage peak, 30 tran-
scripts were identified, of which two genes (UBB and
TNFRSF13B) exhibited significant positive association
with serum BDNF levels after correction of multiple
tests using a false discovery rate of 5%. He then
discussed the putative functional relationship of these
two genes with BDNF: UBB is involved in proteosomal
elimination of cellular waste and is implicated in
Alzheimer’s disease too, while TNFRSF13B is involved
in mediation of inflammation. He concluded that their
findings have suggested biological mechanisms that
regulate serum BDNF levels and possible pathways to
target for treatment of psychiatric illnesses such as
major depression.
The topic of the final talk of the session was Bipolar
Association Case-Control study (BACCS): Focus On
‘‘Schizophrenia’’ candidate genes presented by Dr.
Darya Gaysina from MRC SGDP Centre, London. She
highlighted multiple literature citations that provide
evidence for genetic overlap between different psychia-
tric disorders, especially schizophrenia and bipolar
disorder (BD) (Kirov et al., 2005; Craddock et al.,
2006). Consistent association of genes such as DISC1,
DAOA, DAO, NRG1 and DTNBP1 have been observed
with schizophrenia, and suggestive evidence has been
found for RGS4 and COMT. The objective of her work
was to investigate the genetic association of these
schizophrenia candidate genes with BD. A sample set
consisting of 1587 individuals including 841 patients
with BD and 746 ethnically matched control subjects
recruited from sites in London and Toronto were used for
the study. SNPlex genotyping system was used to
investigate 41 SNPs in total, including DISC1 (8 SNPs),
DAOA (9 SNPs), DAO (1 SNPs), NRG1 (8 SNPs),
DTNBP1 (7 SNPs), RGS4 (3 SNPs) and COMT (6 SNPs).
The results suggest that there is no significant differ-
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ence in allelic or genotypic frequency of any SNP
between BD patients and control individuals. Further,
no association was observed for any haplotype con-
structed between SNPs in these genes also with the BD
phenotype. Dr. Gaysina therefore concluded that
the results do not indicate the involvement of these
polymorphisms with the disease etiology. The sample
size used has 92.6% power to detect an OR of 1.5 for
alleles with 20% frequency. She mentioned that they
would like to further analyze the data for gender and
clinical-subgroup specific associations.
There were several questions for different speakers
and discussion at the end of the session. One question for
Dr. Blakely was about the future implications of his
work in pharmacogenetics. Dr. Blakely commented that
there can be natural variations in genes too for different
strains of mice and the findings are indicating which
pathways to target rather than which specific genes.
Thus, better strategies for SERT manipulation will be
helpful in this regard. Dr. Glahn was asked about the
correlation of brain and serum BDNF levels, and also
why serum levels were used in his study rather than
plasma. Dr. Glahn commented that it is important to
find correlation between brain and serum levels, and he
would want to do that in future, and the reason for using
serum levels was simply its availability. No one has been
able to measure CSF BDNF because of difficulties
obtaining it. It may be possible to use a non-human
primate population to investigate this further. Dr.
Cichon made a comment about importance of picking
rare coding variants for association studies as there is no
dense hapmap coverage for many genes of interest in
bipolar disorders. Dr. Blakely concluded the session by
stressing the importance of functional studies along
with genetic studies for finding causative genes.
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8. IS THERE A GENETIC OVERLAP AMONG
THE PSYCHOSES?
Reported by Emma Dempster
Current nosology separates the two main disorders of
psychosis, bipolar disorder and schizophrenia, into
separate disease entities. However there are many
similarities between these two disorders that have
brought the validity of this dichotomous diagnostic
approach into question.
Dr. Nick Craddock prompted us to consider the
‘‘rethinking of psychosis’’ using data from the recent
bipolar whole genome association study (Wellcome
Trust Case Control Consortium, 2007). In this study
one of the most significant SNPs (P¼ 6.2105) was
located in the gene encoding Gamma-Aminobutyric Acid
Receptor, Beta-1 (GABRB1), however, when the bipolar
cases were split further into those who also made
criteria for schizoaffective/bipolar type (SABP) as
defined by RDC diagnostic criteria, the significance of
this association increased (P¼3.8 106). Further-
more, when the allele frequency of the non-SABP was
compared against SABP there was a significant differ-
ence. This observation stimulated a strategy to be
formulated, to test a specific biological system with a
refined phenotype. In this case, 100 SNPs across various
GABA receptors were genotyped in the case control
study using the refined phenotype. A number of GABA
subunits and receptors were shown to be associated with
SABP: Gamma-Aminobutyric Acid Receptor, Beta-1
(GABRB1); Gamma-Aminobutyric Acid Receptor,
Beta-3 (GABRB3); Gamma-Aminobutyric Acid Recep-
tor, Alpha-5 (GABRA5); and Gamma-Aminobutyric
Acid B Receptor 1 (GABBR1).
Dr. Craddock went on to comment that the DSM-IV
criteria are much more specific than other diagnostic
criteria, and perhaps by using this very specific
diagnostic criteria we are missing shared underlying
biological processes that may be best delineated by using
a broader phenotype. He speculated that the two main
psychosis disorders, schizophrenia and bipolar disorder,
fall on the opposite ends of a spectrum and by looking at
phenotypes that represent ‘‘middle ground’’ we may be
able to elucidate shared underlying biological processes
between the two disorders. However, one of the main
stumbling blocks of this ‘‘middle ground’’ is that it is not
consistently diagnosed.
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Dr. Craddock concluded by proposing a move away
from the 19th century Kraeplin categorical approach to
diagnosis to a more 21st century system based on
biological systems. He did, however, stress that the
association between the GABA genes and broad schi-
zoaffective disorder is not going to change diagnosis but
lead to the identification of target biological systems.
Linking a specific gene to one particular symptom is
unfeasible, but by combining fastidious clinical work-
ups, neuropsychiatry testing and laboratory tests of
course including genetics will be the key to better
diagnosis.
Alexander Niculescu applied his convergent func-
tional genetics approach to tackling the overlap in
psychiatric disorders. This method uses a Bayesian
strategy to cross-interrogate large data sets to prioritize
candidate genes and pathways and identify novel
biomarkers. This method makes use of quantitative
data from a variety of sources, e.g. linkage data,
microarray expression analysis and convergent phar-
macological studies in animals and humans in parallel.
He likens his approach to the internet search engine
‘‘Google’’, the more information on one gene the higher it
is ranked. Niculescu has successfully applied this
approach to three of the main psychiatric disorders,
schizophrenia (Le-Niculescu et al., 2007a), bipolar
(Ogden et al., 2004; Le-Niculescu et al., 2007b) and
alcoholism (Rodd et al., 2007). By examining the overlap
of all these datasets 4 candidate genes, D Site Of
Albumin Promoter-Binding Protein (DBP); Adenosine
A2 Receptor (ADORA2A); Myelin-Associated Oligoden-
drocyte Basic Protein (MOBP); and Coagulation Factor
III (F3), were found in common with schizophrenia,
bipolar, anxiety disorder and alcoholism. Recently they
have extended their approach to investigate peripheral
biomarkers present in the blood and have preliminary
evidence that brain specific genes are heterogeneously
expressed in the blood and have the potential to be used
as biomarkers.
Concentrating more on the specific overlap in the
psychoses Dr. Niculescu introduced his PhenoChipping
strategy (Niculescu et al., 2006). This method, which
uses tools first developed to analyze gene expression
microarray data to investigate correlations between
phenotypes and different quantitative psychiatric
scales, was applied to determine the extent of pheno-
typic overlap between schizophrenia, bipolar and schi-
zoaffective disorder. The resulting conclusion is that,
although heterogeneity in phenotypes exists between
the three diagnoses, there is a substantial overlap of
symptoms, which is not currently addressed in the
current diagnostic scales available.
Alexander Georgi presented his work on premorbid
adjustment in the psychosis. Generally, much of the
research in this area has focused on schizophrenia,
which has found that premorbid adjustment is worse in
individuals who go on to develop schizophrenia and can
be a predictor of clinical presentations and outcome
(Schmael et al., 2007). When Dr. Georgi and colleagues
investigated premorbid adjustment in bipolar disorder
they found a stark contrast to the picture seen in
schizophrenia, in that bipolar patients had excellent
premorbid functioning and were actually better
adjusted than the control sample. Furthermore, no
difference was seen between bipolar patients with
psychosis and those without. These observations appear
to challenge the notion that schizophrenia and bipolar
psychosis share an underlying biology.
William Hennah reported on a recent collaborative
study on one of the most promising candidate genes in
schizophrenia and bipolar disorder, DISC1. This gene
was first identified from a chromosomal translocation
found to be segregating with a broad diagnosis of
psychiatric illness in a large Scottish pedigree (St Clair
et al., 1990 ) Since this first report there has been a
number of linkage and association studied in diverse
populations that support DISC1 as a susceptibility locus
for a wide range of psychiatric phenotypes including
bipolar disorder and schizophrenia but as yet a func-
tional variant has not been uncovered and many of the
studies have little overlap and there has been very few
direct replications.
Dr. Hennah genotyped 75 SNPs in a number of
different European populations (consisting of 1295
schizophrenics and 1262 controls; and 994 bipolar
patients and a further 1004 controls). 60 of the SNPs
genotyped tagged 20 haplotype blocks across the DISC 1
region and an additional 15 SNPs were included that
had putative functionality previously implicated.
Significant association, between bipolar and com-
bined bipolar disorder and schizophrenia, and SNP
rs1538979 was identified in a Finnish sample. Mean-
while, another SNP, rs821577 was found to be asso-
ciated with bipolar disorder in a London sample. Allele
frequency heterogeneity existed between European
populations for SNP rs1538979, but not for rs821577.
The European cohorts were then divided up depend-
ing on if an individual was carrying the risk variant for
rs1538979 or rs821577. This led to the identification of a
further SNP, rs821633 that was significantly associated
with schizophrenia in a subgroup that also carried
the risk allele of rs1538979. Further modeling on the
combination of different risk variants led to the conclu-
sion that if you only carry the rs1538979 or rs821577
‘‘risk’’ variants they are neutral of risk; meanwhile, if
you only carry the rs821633 ‘‘risk’’ allele it decreases
risk. But if you have a combination of rs821633 and
either or both of rs1538979 or rs821577, then it increases
risk. This study highlighted the issue of allele frequency
heterogeneity in differing populations and psychiatric
phenotypes.
The discussion that followed the sessions focused on
the viability of the current DSMIV diagnoses in genetic
research. The main conclusion drawn was that the
current nature of DSMIV diagnosis is unsatisfactory
and that a more modular diagnostic approach would be
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better suited to elucidating the underlying biological
processes. Currently, in psychiatric genetics there is a
common problem of non-replication, therefore not only
are we faced with allele frequency heterogeneity
between populations, but due to differences in diagnosis
there is considerable phenotypic heterogeneity. The
panel agreed that a concerted effort needs to be made to
better describe samples clinically to enable meaningful
replication. The main recommendation from the panel
discussion was that as a community we should make our
voice heard at the international bodies responsible for
the current diagnostic criteria.
References
Wellcome Trust Case Control Consortium. 2007. Gen-
ome-wide association study of 14,000 cases of seven
common diseases and 3,000 shared controls. Nature
447(7145):661–678.
Le-Niculescu H, Balaraman Y, et al. 2007. Towards
understanding the schizophrenia code: an expanded
convergent functional genomics approach. Am J Med
Genet B Neuropsychiatr Genet 144(2):129–158.
Le-Niculescu H, McFarland MJ, et al. 2007. Convergent
Functional Genomics of bipolar disorder: from animal
model pharmacogenomics to human genetics and bio-
markers. Neurosci Biobehav Rev 31(6):897–903.
Niculescu AB, Lulow LL, et al. 2006. PhenoChipping of
psychotic disorders: a novel approach for deconstructing
and quantitating psychiatric phenotypes. Am J Med
Genet B Neuropsychiatr Genet 141(6):653–662.
Ogden CA, Rich ME, et al. 2004. Candidate genes,
pathways and mechanisms for bipolar (manic-depres-
sive) and related disorders: an expanded convergent
functional genomics approach. Mol Psychiatry 9(11):
1007–1029.
Schmael C, Georgi A, et al. 2007. Premorbid adjustment
in schizophrenia–an important aspect of phenotype
definition. Schizophr Res 92(1–3):50–62.
St Clair D, Blackwood D, et al. 1990. Association within
a family of a balanced autosomal translocation with
major mental illness. Lancet 336(8706):13–16.
9. NEW GENETIC APPROACHES TO
STUDIES OF DEMENTIA
Reported by Lan Yu
Chair: Hiroshi Yoneda Discussion Moderator: Mony De
Leon
Five presentations highlighted this session. Dr. Mony
De Leon from New York University gave an overview of
brain imaging and genetics in Alzheimer’s Disease (AD),
highlighting some of the results from his laboratory.
These data showed hippocampus and entorhinal cortex
progressively reducing in size while the temporal horns
of the lateral ventricle were expanding in size in
individuals who progress from mild cognitive impair-
ment (MCI) to AD. However, they also found evidence
for hippocampal atrophy with increasing age in the
normal elderly population, with the hippocampal atro-
phy in MCI and AD subjects to be age independent. In
addition, positron emission tomography (PET) consis-
tently demonstrated a temporo-parietal metabolic
defect in patients with AD and that these changes may
be predictive of who converts from MCI to AD. Several
studies examined the relationship between brain ima-
ging findings and gene mutations. Familial Alzheimer’s
disease (FAD), an early onset AD with autosomal
dominant inheritance was studied by Mosconi and
colleagues in his group. Seven presymptomatic indivi-
duals from FAD carrying mutations in the Presenilin 1
gene were found to have reduced glucose metabolism on
PET that distinguished them from controls, suggesting
that PET measures may serve as biomarkers for the
preclinical diagnosis of AD. Furthermore, the pattern of
metabolic reduction in individuals with the Presenilin 1
gene mutation is consistent with reports on presympto-
matic individuals who are carriers of the (apolipopro-
tein) ApoE 4 allele. When examining the effects of ApoE
genotype on subjective memory complaints (SMC) and
cerebral metabolic rates on PET, Mosconi et al found
that E4 carriers with SMC (E4þ/SMCþ) showed
significant PET alterations compared with E4 negative
individuals, concluding that the ApoE E4 genotype is not
causative but facilitates the metabolic decline, although
the mechanism is unknown. Dr. Andrew Saykin focused
on a Genome Wide Association Study Using Medial
Temporal Lobe Morphology on MRI as the endopheno-
type with a Targeted Pathway Array in older adults at-
risk for Alzheimer’s Disease. He commented that in the
future neuroimaging in combination with genetics will
become important biomarkers for early detection and
medication response in clinical trials. His work is
attempting to examine the memory decline in older
adults particularly in those patients with AD, and to
explore the boundary between normal and pathological
aging. Adults enrolled in a longitudinal study of memory
and aging (40 healthy controls, 40 CC and 40 MCI) were
characterized and studied with neuropsychological
testing and MRI. A genotyping array (Affymetrix MIP)
was designed to assess candidate SNPs for genes in the
following categories: neurodegeneration, neuroinflam-
mation, neurotransmitter receptors, cerebrovascular
and metabolic/endocrine factors, plasticity/repair and
growth factors and the molecular substrates of cognition
and memory/long term potentiation. The CC (cognitive
complaint) and MCI groups showed similar decreased
gray matter density relative to the HC group on whole
brain analysis. Manually segmented hippocampal
volumes were significantly reduced only in the MCI
group. Significant Dx by SNP interactions with p< .001
were observed in multiple candidate pathways. Parti-
cularly notable were associations with hippocampal
volumes (R more frequent than L). A subset surviving
stringent multiple testing corrections and threshold
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issues are being examined in ongoing statistical ana-
lyses. He concluded that allelic variation in targeted
pathways accounts for significant variance in hippo-
campal morphology in those at risk for AD. Medial
temporal lobe gray matter density appears more
sensitive than volume to early preclinical stages (i.e.,
cognitive complaint group), however hippocampal
volume shows a greater indication of genetic influence.
Future directions are to look for genetic predictors of
hippocampal volume changes and to explore polymorph-
isms that relate to changes in brain activation after
medication. The specific pathways and alleles, however,
were not specified, as the final data analyses are still in
progress. One issue that arose in the discussion was
whether the same genes that influence hippocampal
volume in AD have an influence in hippocampal
reduction in other conditions, such as schizophrenia.
He concluded that there may be a final common pathway
for many etiologies to have an effect on this venerable
structure, but that a genetic overlap between schizo-
phrenia and AD was unlikely.
The third speaker, Dr. Gary Beecham reported on
another whole-genome association study using Late-
Onset Alzheimer Disease (LOAD) as the phenotype.
LOAD is the most common cause of dementia and there
are over 5 million individuals affected with LOAD in the
US. The lifetime risk is 10–15% in the general popula-
tion and the prevalence doubles every 5 years after age
60. Genetic studies have estimated the heritability of
LOAD to be 80%, however, APOE is the only consensus
LOAD risk gene which accounts for at most 50% of the
genetic effect. Thus, a genome-wide association (GWA)
study for LOAD may be useful to detect other AD risk
loci. Beecham’s group used the Illumina Infinium plat-
form to genotype 518 cases and 531 controls for 550,000
SNPs. They implemented numerous quality control
tests to ensure the integrity of the data, and tested for
association using the Armitage’s Trend test. One SNP on
chromosome 12 (rs11610206) and three APOE SNPs
were significantly associated at the 0.05 level (multiple
testing corrected). Rs11610206 lies directly under the
narrow covariate-based linkage peak on 12q and is
located near the Vitamin D Receptor (VDR) gene
previously associated with AD. Thus, these results
provide convincing evidence for an AD risk locus on
12q13.
The fourth speaker, Dr. William Kremen, spoke on the
effects of the ApoE genotype on brain and cognition in
the sixth decade of life. Much research suggests that
signs of AD are present long before it can be diagnosed.
The ApoE genotype appears to be a risk factor for AD.
Almost all adult studies of ApoE genotypes and cogni-
tion include individuals over 60. In older adults, E4
carriers may manifest increased cognitive asymmetry.
Moreover, general cognitive ability may be affected by
both aging and ApoE genotype, but most studies
inadequately address this potential confound. To exam-
ine the relationship of ApoE genotype to episodic
memory, verbal-visual-spatial episodic memory asym-
metries, and selected brain structures, he and his
colleagues compared E4þ and En4- in 626 male twins
in their 50s. They also compared verbal and visual-
spatial episodic memory and verbal-visual asymmetry
scores after adjusting for cognitive ability at age 20.
Compared with E4- individuals, E4 carriers performed
more poorly on verbal, but not visual-spatial memory,
manifested greater cognitive asymmetry, and had more
concerns about memory. At age 20, E4 carriers had
higher general cognitive ability than E4- individuals,
and current memory differences were enhanced after
adjusting for age 20 cognitive ability. Brain caudate and
putamen volumes were smaller in E4 carriers, but they
had less white matter abnormalities. Results strongly
suggest that APOE-4 related impairments are risk
factors for dementia, but not just signs of prodromal AD.
The final presentation was given by Dr. Ryo Kimura
who focused on the DYRK1A gene, encoded in the
chromosome 21 Down syndrome critical region. This
gene bridges beta-amyloid production and tau phos-
phorylation in AD. Dr. Kimura and his research group
scanned chromosome 21 for genetic associations to
LOAD using 374 Japanese trisomy 21 patients and 375
population-based controls, because trisomy 21 is known
to be associated with early deposition of b-amyloid (Ab)
in the brain. Among 417 markers spanning 33Mb, 22
markers showed associations with either the allele or
the genotype frequency (P<0.05). Logistic regression
analysis with age, sex and ApoE-epsilon4 dose sup-
ported genetic risk for 17 markers, of which eight
markers were linked to the SAMSN1, PRSS7, NCAM2,
RUNX1, DYRK1A and KCNJ6 genes. In logistic regres-
sion, the DYRK1A (dual-specificity tyrosine-regulated
kinase 1A) gene, located in the Down syndrome critical
region, showed the highest significance [OR¼ 2.99 (95%
CI: 1.72–5.19), P¼0.001]. DYRK1A mRNA level in the
hippocampus was significantly elevated in patients
with AD when compared with pathological controls
(P<0.01). In addition, DYRK1A mRNA levels were
increased with A-beta loading in the brains of transgenic
mice at 9 months of age. In human neuroblastoma cells,
A-beta induced an increase in the DYRK1A transcript,
which also led to tau phosphorylation at Thr212 with
overexpression of tau. Therefore, the upregulation of the
DYRK1A transcription likely results from Abeta load-
ing, further leading to tau phosphorylation. They
concluded that DYRK1A could be a key molecule
bridging beta-amyloid production with tau phosphor-
ylation in AD.
10. NEW PERSPECTIVES ON SCHIZOPHRENIA
CANDIDATE GENES
Reported by Anna Alkelai
Introduction: There are four main strategies to search
for genes for schizophrenia: studies of chromosomal
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abnormalities, genetic linkage studies, association
studies and convergent genomics (Owen et al., 2005).
Recently the field of schizophrenia genetics has focused
on association studies using functional or positional
candidate gene approaches. In this session five speakers
presented their work based on association studies, with
the main goal of identifying schizophrenia susceptibility
genes.
Presentations: The first presenter was Dr. Nigel
Williams. 22q11 deletion syndrome is the most common
known microdeletion in humans. It is also the most
common known genetic risk factor for schizophrenia
(Gothelf et al., 2007). The previously published study by
Paylor et al. (2006) revealed two strong candidate genes
(TBX1/GNB1L) for psychiatric disease in this 22q11
region. The main goal of Dr. Williams’s study was to test
the hypothesis that variants in these two genes confer
susceptibility to develop psychosis. In this study the
association analysis of SNPs within GNB1L and TBX1
genes was performed in a schizophrenia case control
sample and was replicated in two independent schizo-
phrenia case control samples and also in schizophrenia
parent proband trios. Significant male specific genotypic
association was observed in all replication samples. In
addition, it was shown that the most associated SNP was
correlated with expression of the GNB1L gene. The
SNPs showing the strongest association in males in
schizophrenia case/control samples was also associated
with psychosis in an additional male 22q11DS sample.
These data suggest that increased risk of developing
psychosis results from genetic variation at TBX1/
GNB1L locus and is mediated in a dosage sensitive
manner possibly via gene expression.
The second presenter was Dr. Jubao Duan. A
previously published genome-wide linkage scan of 409
families with schizophrenia revealed suggestive evi-
dence of linkage at chromosome 8p23.3-p21.2 (Suarez
et al., 2006). In Dr. Duan’s research a dense LD
mapping association study of this region was performed
in a large schizophrenia and schizoaffective disorder
case control sample. Nominally significant association
was detected for several SNPs in or near the CSMD1,
MFHAS1, PSD3 or EBF2 genes with the best result for
SNPs near EBF2. In addition, copy number variants in
the same sample were analyzed and a rare 72 kb deletion
in MSR1 was found to be overrepresented in cases with
nominal significance. Genotyping of additional SNPs in
the region did not improve the significance. It was
assumed during discussion that if all the results are true
positives, then a number of nominally associated genes,
each one probably with small effect, could be involved in
schizophrenia susceptibility.
The third presenter was Dr. Anna K Kahler, who
studied the putative association between schizophrenia
and gene variants involved in the neuronal migration
process, in three Scandinavian case control samples.
There is evidence in the literature that schizophrenia is
a neurodevelopmental disorder, and brain abnormal-
ities in patients with schizophrenia could be due to an
abnormal neuronal migration (Weickert et al., 1998).
SNPs in 18 genes were genotyped and nominally
significant association for several SNPs in both the
RELN gene and a gene encoding an adhesion molecule
was identified. It was mentioned during the presenta-
tion that genotyping of additional SNPs could be done to
improve significance. This study presented additional
support for the previously reported schizophrenia
candidate RELN and suggested a possible new candi-
date gene.
The fourth presenter was Dr. Stephen Glatt. Prior
case control studies found a reliable effect of one DRD2
polymorphism on risk for schizophrenia (Arinami et al.,
1994). In Dr. Glatt’s study the first family-based
association study of schizophrenia with haplotype-
tagging and all three known non-synonymous poly-
morphisms in DRD2 was performed. Significant evi-
dence even after Bonferroni correction was found for one
polymorphism and two haplotypes. These results
further strengthen the candidacy of DRD2 as a schizo-
phrenia risk gene.
The fifth presenter was Dr. Masashi Ikeda. Prior
studies identified Neuregulin1 as a candidate gene for
schizophrenia (Stefansson et al., 2002). In Dr. Ikeda’s
study three-stage association analysis with tagging
SNPs in Neuregulin1 gene was performed in a large
Japanese sample. This study did not replicate the
association between the Neuregulin1 gene and schizo-
phrenia susceptibility in the studied population.
Discussion: It was noted during the session discussion
that replications in other independent samples are
needed to confirm the results of the presented studies,
and that it is essential to combine association with
functional analysis. It was also suggested that it may be
of benefit to re-genotype and combine samples which
were used in early studies, since many aspects have been
improved since then: sample sizes have increased,
genotyping technology has improved, and knowledge
from the human genome project has accumulated. It was
also mentioned that the discovery of susceptibility genes
for schizophrenia in the future will hopefully improve
the understanding of the disease, will propose more
efficient treatments, and will help to find individuals at
risk to be affected with genetic testing. Since the clinical
implications of genetic findings are not yet clearly
visible, psychiatric genetics and medical clinic still work
as independent fields. It was proposed during the
session discussion that it may be too conservative to
wait for the clear and obvious genetic findings. It was
proposed that physicians have to be more involved in
genetic research field and some clinical implications
should be considered.
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11. THE GENETICS OF SUBSTANCE ABUSE
Reported by Marlon P. Quinones
Substance abuse is now recognized as a chronic,
relapsing disease characterized by compulsive drug
seeking. Drug addiction costs to our nation more than
$484 Billion per Year1. Over half (51%) of America’s
teenagers have tried an illicit drug by the time they
finish high school. In 2003, an estimated 71 million
Americans reported being current users of a tobacco
product, 14.6 million people were current users of
marijuana, and nearly 17.6 million adults in the United
States are alcohol-dependent or have problem with
alcohol. Drug addiction shares many features with other
chronic illnesses, including a tendency to run in families
(heritability), an onset and course that is influenced by
environmental conditions and behavior, and the ability
to respond to appropriate treatment, which may include
long-term lifestyle modifications.
Indeed, human studies of addictive behaviors have
clearly implicated environmental, genetic influences
and their interactions in disease pathogenesis. All these
pathogenic factors were addressed in the ISPG’s meet-
ing session on genetics of substance abuse. The session
chair was Dr. Ming Tsuang, Professor of Psychiatry,
University of California, San Diego, and Director,
Institute of Behavioral Genomics. The discussion mod-
erator was Dr. Kenneth Kendler, Professor of Psychia-
try Virginia Institute for Psychiatric and Behavioral
Genetics, Virginal Commonwealth University.
The first talk in the session addressed the need for the
development of relevant animal models to study the
mechanisms by which genes affect the susceptibility to
substance abuse. In his talk, Dr. Eric Vallender
presented research demonstrating how investigators
can use rhesus monkeys to dissect the effects of single
nucleotide polymorphisms (SNPs) on the function of
genes whose products have a critical role in neurotrans-
mitter systems. In principle, rhesus monkeys with
overlapping yet distinct constellations of disorder-
related alleles that mimic in effect orthologous human
alleles could be utilized to both clarify the genetic
interactions influencing disorder-related phenotypes as
well as serve as a preclinical platform for the develop-
ment of much-needed human pharmacogenomics-based
treatment interventions. Some of the examples pre-
sented in the session included SNPs in the Tryptophan
hydroxylase (TPH)-2 gene, a second form of TPH
responsible for serotonin synthesis in the brain. SNPs
in the TPH2 have been increasingly implicated as
contributors to the etiology of various psychiatric
disorders. Notably, the rhesus’ TPH2 gene also
has functional SNPs. Dr. Vallender also commented on
other functional polymorphisms identified on the rhe-
sus’ serotonin transporter and monoamine oxidase-type
a genes. He postulated that collectively, polymorphisms
in these genes are likely to influence substance abuse
and that we can understand the mechanisms underlying
their effects using rhesus monkeys. An interesting
question from the audience was whether rhesus mon-
keys have a degree of genetic variability as great as that
seen in humans. Dr. Vallender commented that there
seem to be extremely high degree of polymorphisms in
the Indian macaques that the authors have used for
their studies and that aids in the use of these animals as
genetic models for the detection of genetic variability in
susceptibility to substance abuse.
The next talk described new data on the genetic
variation of specific genes and the risk for alcohol
dependence. The rational for this work is provided by
data from twin, family, and adoption studies demon-
strating a major genetic influence on vulnerability to
alcoholism. Dr. John Nurnberger, from Indiana Uni-
versity School of Medicine, presented data derived
using large, genetically informative pedigrees from the
Collaborative Study on the Genetics of Alcoholism
(COGA) (Dick et al., in press). Since 1989 COGA has
been federally funded aiming to identify specific
genes underlying vulnerability to alcohol dependence.
The COGA investigators, in the course of carrying
out their linkage studies of alcoholism, have assembled
a collection of >300 extended families densely1Data source: National Institute on Drug Abuse (NIDA) website.
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affected by alcoholism, consisting collectively of >3000
individuals. They have collected extensive clinical,
neuropsychological, electrophysiological, biochemical,
and genetic data, and established a repository of
immortalized cell lines from these individuals, to serve
as a permanent source of DNA. Dr. Nurnberger’s
broadly commented on specific single genes implicated
in the susceptibility to alcohol abuse including acetate
nonutilizing (ACN)-9, gamma-aminobutyric acid recep-
tor A alpha-2 subunit (GABRA2; Dick et al., 2006a and
b), alcohol dehydrogenase (ADH)-4 (Edenberg et al.,
2006), cholinergic receptor muscarinic (CHRM)-2(Wang
et al., 2004; Jones et al., 2004), 5, glutamate receptor,
metabotropic (GRM)-8; and how information about
these gene-candidates, was derived using different,
but equally powerful methodology for the dissection of
the genetics of alcohol dependence. Some of approaches
included saturation genotyping with SNP’s in a linkage
region, an endophenotype-based approach, or a ‘‘Con-
vergent Functional Genomics’’ approach that cross-
matches gene expression data from rodent models with
human genetic linkage data for the preliminary identi-
fication of gene-candidates.
An example of the endophenotype approach relates to
the studies on GRM8 as a candidate gene. Due to the
richness of data collected in the COGA cohort, it is
possible to look for more proximal phenotypic correlates
of gene variation (i.e., endophenotypes), which collec-
tively are thought to be associated with alcohol depen-
dence. Evidence suggests the P3 amplitude of the event-
related potential and its underlying superimposed
event-related oscillations, primarily theta (4–5 Hz)
and delta (1–3 Hz) energy bands, are endophenotypes
for the risk of alcoholism and other disinhibitory
disorders. Major neurochemical substrates contributing
to theta, delta rhythms and P3 involve strong GABAer-
gic, cholinergic and glutamatergic system interactions.
GRM8 was selected as candidate because it maps at
chromosome 7q31.3-q32.1 under a peak region pre-
viously identified as having significant linkage using a
genome-wide linkage scan. It was reported that using a
family based association test, there was a significant
genetic association between multiple SNPs in the GRM8
gene and event-related theta power to target visual
stimuli. This was the case even after correction for
multiple comparisons by false discovery rate (FDR).
Base on these results it was concluded that variation in
GRM8 could be involved in modulating event-related
theta oscillations during information processing and in
vulnerability to alcoholism.
Dr. Nurnberger also commented on interesting
results related to other genes linked to alcohol depen-
dence identified using other approaches. For instance,
mice with a homozygous deletion the clock gene (and a
transcription factor) D-box Binding Protein (DBP) were
found to have a baseline lower locomotor activity, blunted
responses to acute methamphetamine administration,
and gain less weight over time compared to wild-type
controls, analogous to DSM criteria of depression in
humans. In response to a chronic stress paradigm, DBP
KO mice exhibit a diametral switch in these phenotypes,
resembling phenotypic aspects of bipolar disorder.
Notably, level of DBP in the frontal cortex differs
between alcohol preferring vs. non-alcohol preferring
rats. Together, the data available so far suggested that
DBP could be an important candidate for alcoholism and
co-morbid psychiatric disorders. Dr. Nurnberger men-
tioned recently published associations between (i) alpha
synuclein and alcohol craving, a common, although not
uniform, feature of alcohol dependence; (ii) dynorphin,
mu-opioid receptor, GABRA2 CHRM2 and alcohol
dependence; and (iii) GABRA1 with several of the
drinking behavior phenotypes, including COGA alcohol
dependence, history of blackouts, age at first drunken-
ness, and level of response to alcohol.
The next speaker continued with this line of research.
Dr. Brien Riley, from the Departments of Psychiatry and
Human Genetics and Molecular Laboratory at Virginia
Institute for Psychiatric and Behavioral Genetics,
described results of fine-mapping of a 18mb alcohol
dependence susceptibility locus on 4q22-q32 in the Irish
Affected Sib-pair Study of Alcohol dependence (IASP-
SAD). This study includes 1414 individuals from 591
families ascertained in Ireland. Alcohol dependence was
assessed among 1201 probands and affected siblings
with use of the Semi-Structured Assessment for the
Genetics of Alcoholism and among 213 parents with use
of a modified version of the Structured Clinical Inter-
view for DSM. SNPs in a number of genes in the region
showed modest evidence of association with the diag-
nosis of alcohol dependence. The strongest association
signal observed for the AD diagnosis was with SNPs in
the neuronal ankyrin 2 (ANK2). Several lines of evi-
dence support this putative association. First, a related
gene, ankyrin repeat and kinase domain containing 1
(ANKK1), was recently reported associated with AD in
the COGA sample. Second, ankyrins are thought to link
membrane-bound proteins to the underlying spectrin-
actin cytoskeleton, and Eps8 knockout mice show re-
sistance to both the acute intoxicating effects of ethanol
and ethanol-mediated actin remodeling. Finally, Men-
delian mutations in ANK2 cause long-QT syndrome
cardiac arrhythmia. The QT interval is prolonged in
alcoholics (and this can persist in abstinence) and acute
ethanol increases the QT interval in controls. ANK2 also
showed association with multiple phenotypes related to
AD, including nicotine dependence.
However, the chromosome 4q linkage in this sample
was strongest when analyzing a quantitative trait of
number of AD symptoms endorsed (ADSx). A different
locus, the dickkopf homolog 2 (DKK2) gene gave
strongest evidence for association with ADSx, and was
specific to the ADSx phenotype. DKK2 has not pre-
viously been implicated in alcohol-related phenotypes.
Completing the series of genetic association studies
focused on the genetic basis of alcohol dependence,
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Dr. Danielle Dick, Departments of Psychiatry, Psychol-
ogy, and Human Genetics, Virginia Institute for
Psychiatric and Behavioral Genetics at Virginia Com-
monwealth University, presented data on a systematic
screen of a linkage region on chromosome 7 in the COGA
study. A panel of 1536 SNPs were genotyped to tag
linkage disequilibrium bins across a 2 LOD support
interval around the alcohol dependence linkage peak on
chromosome 7. Four of the eight most significant SNPs
from the screen were all located in or very near the ACN9
gene. Additional genotyping across ACN9 was con-
ducted and identified multiple variants with significant
evidence of association with alcohol dependence. Little
is known about the role of ACN9 in humans; Data from
yeast suggest that ACN9 is involved in acetate utiliza-
tion and gluconeogenesis. This may suggest a plausible
role for ACN9 in the predisposition to alcohol depen-
dence (Dick et al., in press).
Complementing the work presented by other speak-
ers on the identification of genetic determinants of
substance abuse, Dr. Kendler spoke on gene-environ-
ment interactions. His group used retrospective assess-
ments of life history from 1,796 male twins, aged 24–62
from the population-based Virginia Twin Registry. Dr.
Kendler’s data suggest that in early adolescence, twin
resemblance for nicotine, alcohol and cannabis use was
entirely environmental in origin. Nevertheless, with
age, genetic effects became increasingly important in
influencing substance use while shared environmental
effects diminished and then disappeared. But, what
kind of environmental influences have such a powerful
influence in the susceptibility to substance abuse?
Preliminary evidence suggests that peer group
deviance; drug availability and parental monitoring
substantially mediate shared environmental effects on
psychoactive substance use.
Indeed, a very fascinating aspect of Dr. Kendler’s
work relates to his research on peer group deviance. To
conduct research on peer deviance, twins reported how
many friends they had had in each time period who
smoked, drank, cut classes often, used or sold drugs,
stole things, or got in trouble with the law (collectively
indicators of deviance). Then, concordance rates
between monozygotic and dizygotic twins in the like-
lihood of choosing the same kind of friends (endorsing
more or less deviance indicators) were calculated. Given
that there was a higher concordance rate between
monozygotic and dizygotic twins, the data suggested
that there was a genetic inclination to select certain
types of people as their friends. Remarkably, this finding
is closely linked with susceptibility to substance abuse.
The genetic inclination to choose peers that use
substances could increase risk by determining the levels
of exposure substances. Regarding the modulatory
effects of age, estimates from Kendler’s work revealed
that for 8–11 year old children, genes explained 30% of
their choice in friends, with that percentage rising to
about 50% from age 15–25, as people matured into
independent adults. These data suggest that as indivi-
duals grow older, genetic factors play an increasingly
more important role in the social world that they create
for themselves.
Another critical factor addressed by the speaker was
the inter-relationship between personal deviancy –
assessed by symptoms of conduct disorder (CD) – and
peer group deviance. It was suggested that genes could
act to influence CD, which through social selection
impacts on peer group deviance. Shared environment
could impact on peer group deviance, which, via social
influence, alters risk for CD.
From the discussion that followed Kendler’s work,
and as part of the final discussion of the material
presented in the session, it became clear that there is a
great interest on defining possible genes that influence
personal and peer group deviance; as well as to model
gene and environment interactions. The studies that
have been conducted up to date have begun to reveal the
genetic underpinnings of substance abuse. Animal
models are extremely powerful helping to identify
candidate genes and allowing testing of the mechanisms
by which genetic variation influence gene function.
There seemed to be a consensus that future studies
should take into account environmental influences, and
to examine the possible genetic determinants of sub-
stance abuse as dynamic factors, having effects that may
be of importance only at specific developmental stages.
Indeed, more research is needed to determine whether
social factors determine initial exposure to substances of
abuse while genetic determinants influence persistence
use and dependency.
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12. FUNCTIONAL CHARACTERIZATION OF
GENES/VARIANTS INVOLVED IN
NICOTINE DEPENDENCE
Reported by Tania DasBanerjee
This was a symposium comprised of four speakers and
aimed at understanding the genetics of nicotine depen-
dence.
The first presentation was Genome wide association
and candidate gene study for nicotine dependence given
by Laura Bierut. Nicotine dependence is a many step
process: first comes initiation, then smoking, and finally,
after smoking about 100 cigarettes, nicotine depen-
dence. Since smoking is the leading source of prevent-
able death in the US and twin studies have consistently
demonstrated strong genetic contributions to smoking,
this study was undertaken. This presentation described
the NICSNP project, a hybrid study of genome wide
association (GWA) coupled with analysis of candidate
gene results.
The study sample consisted of 1050 nicotine depen-
dent cases and 879 non-dependent smokers as controls.
All the participants were selected from two community-
based studies, the Collaborative Genetics Study of
Nicotine Dependence (US) and the Nicotine Addiction
Genetics Project (Australia). Subjects were chosen on
the basis of their Fagerström Test for Nicotine Depen-
dence (FTND) scores: nicotine-dependent smokers had
to have a FTND score >4 (mean FTND score¼ 6.3)
while the controls (non-dependent smokers) had to have
a lifetime FTND score¼0. The GWA study performed
pooled genotyping of 2.4 million single nucleotide
polymorphisms (SNPs) followed by individual genotyp-
ing of top 40,000 signals. In the candidate gene study,
individual genotyping was conducted in 300 genes
chosen on the basis of their known functional signifi-
cance.
The GWA study did not identify any significant SNPs
(odds ratio 1.2–2.1) although the results did identify
novel loci not previously associated with the risk for
nicotine dependence. The candidate gene study revealed
significant associations of the GABRA4, CHRNB3,
CHRNA3 and CHRNA5 genes with nicotine depen-
dence. In the alpha 5 nicotinic receptor (CHRNA5), a
common variant which causes an amino acid change
(D398N) in the receptor protein, is highly associated
with nicotine dependence. The D398N variance was also
replicated in the COGA (Collaborative Study on the
Genetics of Alcoholism) samples. It was shown that the
D398N variance differs in allele frequency. It is only
seen in Europeans, highest among the French, and is not
seen in Africans and Asians. These findings are a major
step towards our understanding of the genetics of
nicotine dependence. The genetic data from this study
are available for further analyses by others in the
scientific community.
The second presentation was Nicotinic receptor poly-
morphisms and nicotine sensitivity in mice by Jerry
Stitzel. A naturally occurring non-synonymous poly-
morphism (T529A) in the nicotinic receptor alpha4
subunit gene (Chrna4) has been known to be linked to
various measures of nicotine sensitivity, nicotinic
receptor function and ethanol-induced depression. This
study utilized Chrna4 T529A knock-in mice to validate
the role of this polymorphism in modulating sensitivity
to nicotine and nicotine receptor function.
Adult mice possessing the T529A allele of Chrna4
differ from controls in nicotine-induced hypothermia
but not expression of alpha4beta2 Chrna4 in the whole
brain. Preliminary data also shows that the T529A
polymorphism influences the function of the alpha4-
beta2 nicotinic receptors in selected brain regions by
shifting the receptor conformation from low sensitivity
to high sensitivity. The presence of the T529A allele
alters sensitivity to reinforcing properties of nicotine.
T529A homozygotes developed nicotine conditioned
place preference and failed to develop conditioned taste
aversion while A529 homozygotes developed condi-
tioned place aversion as well as conditioned taste
aversion. Adult mice possessing the T529A allele of
Chrna4 consumed more nicotine by choice than their
A529 littermates. Since tobacco consumption begins in
adolescence, the above experiments were repeated in
adolescent mice with the T529A polymorphism and their
A529 littermates. Preliminary results show that ado-
lescent mice homozygous for the T529A allele of Chrna4
consume more nicotine by choice than do their A529
homozygous littermates. It was hypothesized that the
T529A variant affects Chrna4 receptor function by
modulating the phosphorylation of the serine 530
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residue of the receptor. Whether S530 is actually
phosphorylated and how T529A modulates S530 phos-
phorylation is under investigation. Also, whether the
T529A polymorphism affects the valence of nicotine in
adolescent mice is yet to be addressed.
The third presentation, Nicotine-dependent behaviors
and TRP channels in C. Elegans was given by Shawn
Xu. Since the underlying genetic mechanism by which
nicotine induces profound behavioral changes in mam-
mals is not well understood, this report used the
nematode C. elegans as a genetic model to characterize
nicotine response. C. elegans is a good system to study
since they are genetically 40% homologous to humans,
have a much simpler nervous system and their wiring
pattern is completely known. It has been shown that the
worms exhibit similar behavioral responses to nicotine
as those observed in mammals, including acute
response, withdrawal and tolerance. It has also been
shown that repeated intermittent nicotine exposure
sensitizes these worms response to nicotine, which is
important in the developing of nicotine dependence.
Thus this system can be used as a model to study genes
underlying these behavioral responses.
Nicotine dependence in C. elegans requires the
presence of nicotine receptors. C. elegans contains 29
nicotinic acetylcholine receptor (nAChR) genes and
mutation in the acr15 and acr16 genes is known to
reduce nicotine dependence through reduction in sensi-
tization to nicotine. Remarkably, transgenic expression
in C. elegans of the mouse nAChR a4b2, which is known
to be critical for nicotine dependence in mice, can rescue
the defect of C. elegans nAChR mutants in response to
nicotine. In an effort to identify any novel protein
regulating nicotine responses, it was found that mutant
worms lacking a TRPC channel are defective in response
to nicotine. This defect could be rescued by a human
TRPC channel, suggesting that TRPC channels are
functionally conserved in nicotine responses.
TRPC channels are expressed in the command
interneuron and are required for nicotine-dependent
behavior. A hypothetical model in place suggests that
when nicotine acts on nAChR on dopamine neurons it
causes the release of dopamine from these neurons. This
dopamine then binds to and activates metabotropic
dopamine receptors on command interneuron, which
then through PLC and DAG activate the TRPC
channels. The calcium transients created by TRPC
channels modulate the behavioral response to nicotine.
This study thus revealed an unexpected role for TRPC
channels in nicotine-dependent behavior and raises the
possibility that these channels might regulate nicotine
dependence in mammals.
The fourth and final presentation was on: The
cannabinoid receptor 1 (CNR1) gene association with
smoking initiation, nicotine dependence and other
substance use by Xiangning Chen. The endogenous
cannabinoid system has been implicated in drug addic-
tion in animal models. The CNR1 gene is mainly
expressed in the central nervous system (CNS) and is
known to be associated with substance abuse, schizo-
phrenia and Parkinson’s disease. This study investi-
gated the association of CNR1 with smoking initiation
(SI), nicotine dependence (ND) and other substance
abuse by typing 10 SNPs in two independent samples,
VAND and VAANX. Allelic and haplotype associations
were performed.
In the VAND sample (n¼688), selected for low and
high levels of ND, (on the basis of FTND scores), 10 SNPs
were typed in the CNR1 gene. In association analyses,
two markers (rs6928499 and rs2023239) were signifi-
cant for both SI and ND and the association was sex
specific. In multi-marker haplotype analyses, highly
significant haplotype associations were found for mar-
ker combination rs6928499-rs2023239-rs12720071-
rs806388. In the VAANX sample (n¼ 961), selected by
anxiety and neuroticism, the same 10 SNPs were typed.
The same two SNPs showed the same sex-specific
associations with SI, but no association with ND. In
haplotype analyses, significant results were obtained for
the same 4-marker combination for both SI and ND.
Single marker and haplotype associations’ analyses
were also done for other substance use/abuse (alcohol
abuse, stimulant use, sedative use, and cannabis use)
and nominally significant results were observed for
multiple substances. These associations were also sex-
specific.
These results suggest that the CNR1 gene may be
associated with SI, ND and substance use/abuse and
that these associations may be sex-specific but not
substance specific. There is an estrogen response
element (ERE) in the CNR1 gene which may account
for the sex-specific effects.
13. GENETIC INFLUENCE ON ADULT
NEUROGENESIS
Reported by Dylan Glubb
It has been well established that adult neurogenesis
takes place in the olfactory bulb and the dentate gyrus of
the hippocampus (Gould, 2007; Kempermann and Gage,
1999; Lledo and Saghatelyan, 2005; Ming and Song,
2005; Schinder and Gage, 2004; Temple and Alvarez-
Buylla, 1999). Over 9000 new cells are generated every
day in the dentate gyrus of a young adult rat (Cameron
and McKay, 2001) but these numbers decline with age
(Klempin and Kempermann, 2007). Experience also
modulates adult neurogenesis. For example, physical
exercise enhances adult neurogenesis in the hippocam-
pus (van Praag et al., 1999) whilst motherhood in female
rats can inhibit neurogenesis (Leuner et al., 2007).
Stress hormone levels are affected by experience and
may determine the resulting change in neurogenesis.
Extended running in hypertensive rats, which is
associated with an increase in plasma corticosterone
levels, actually inhibits exercise induced hippocampal
neurogenesis (Naylor et al., 2005). Neurogenesis is
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suppressed in lactating postpartum females until
weaning but this decrease in cell proliferation is
dependent on elevated glucocorticoid levels associated
with lactation (Leuner et al., 2007). Parenting may not
always have a negative effect on neurogenesis. Dr Gould
commented on the observations of enhanced dendritic
spine density during fatherhood in male marmosets.
Thus, it appears that neurogenesis and structural
plasticity are characteristic of the adult mammalian
brain and these phenomena are modulated by experi-
ence.
There is evidence for adult neurogenesis in brain
regions other than the hippocampus and olfactory bulb.
Adult neurogenesis has been observed in the neocortex,
striatum, amygdala and substantia nigra but some
studies have not been able to replicate these findings
(Gould, 2007). In the case of neurogenesis in the adult
neocortex, Dr Cameron presented evidence to show
neurogenesis occurs there at a similar rate to that in the
dentate gyrus. These newborn neurons in the neocortex
are immunoreactive for GABA/GAD-67 providing evi-
dence that theses cells are GABAergic interneurons
(Dayer et al., 2005). Expression of calcium-binding
proteins calbindin and calretinin has also been detected
and the temporal expression pattern of these proteins
may be indicative of the maturation stage of the new
neurons (Dayer et al., 2005). Over 90% of proliferating
cells in the neocortex express NG2 which is considered to
be a marker for oligodendrocyte precursors. However,
not all NGþ cells differentiate into glial cells and some
NGþ cells differentiate into neurons. Therefore, Dr
Cameron concluded that these NGþ cells generate
GABAergic interneurons in the neocortex.
Neurogenesis and the making of memories
The hippocampus plays an important role in the
learning and the consolidation of memory and the
survival of newborn neurons in the hippocampus may
be associated with this. One type of learning that is
dependent on the hippocampus is the trace eyeblink
conditioning task in which there is an interval of time
between the presentation of the conditioned and
unconditioned stimuli. In the adult rat dentate gyrus,
the number of new neurons maintained after this
hippocampus-dependent task is significantly greater
than the number which survive after a hippocampus-
independent task (Gould et al., 1999). The question is
whether the learning-induced effects of neurogenesis
require a temporal gap between stimuli. To answer this
question two alternate versions of trace and delay
eyeblink conditioning were developed. In the very long
delay eyeblink conditioning task, the duration of the
conditioning stimulus is nearly doubled which makes
the task hippocampus-dependent and the survival of
new neurons is increased (Leuner et al., 2006). In the
other task, trace eyeblink conditioning is made hippo-
campus-independent by training the rats with a delay
arrangement and there is no enhanced survival of
neurons. These findings indicate that associative learn-
ing rather than training increases adult neurogenesis,
regardless of a temporal gap between stimuli. Indeed, it
may be the acquisition of new information which
prevents these new neurons from dying (Dalla et al.,
2007) and the quality of the learning may relate to the
number of neurons which survive (Sisti et al., 2007).
Egr1 and learning
Egr1 is an immediate early gene which is up-
regulated during associative learning and long term
potentiation (Davis et al., 2003). Expression of this gene
may be related to neuronal activation (Jessberger and
Kempermann, 2003) and Egr1 is also up-regulated
following behavioral training using the Morris water
maze (Pollak et al., 2005). Other evidence also shows
that this gene may play a critical role in learning and
memory (Jones et al., 2001). mRNA expression of Egr1 in
the hippocampus is greater in animals which undergo
long varied training in the Morris water maze compared
with those which receive unvaried training. However,
cage controls have higher expression of Egr1 than both
groups. Dr Cameron suggested that this effect in the
control animals may be due to sleep-based consolidation
of memories or related to the lack of stress/low
corticosteroid levels that the animals experienced.
There also appears to be an age dependence of Egr1
expression in newborn neurons. A maturation period of
several weeks is needed before new neurons in the
hippocampus will express Egr1 after neuronal stimula-
tion by kainate (Jessberger and Kempermann, 2003).
Akt kinase signaling in learning and synaptic plasticity
Akt is a serine/threonine kinase which regulates
neuronal cell survival, proliferation and differentiation
(Peltier et al., 2007; Zhao et al., 2006), and neuronal
excitability (Chae et al., 2005). This kinase has lower
activity in the prefrontal cortex of depressed suicide
victims (Karege et al., 2007) and is dysregulated in
neurodegeneration (Bi et al., 2005; Colin et al., 2005).
Activation of Akt may play a role in synaptic plasticity
and the consolidation of memory (Horwood et al., 2006).
Dr Franke discussed experiments in which Akt1(/)
and Akt-mutant transgenic mice showed impaired
learning in passive/avoidance tasks. Both types of mice
also have decreased long term potentiation in the
hippocampus. The NMDA NR1 subunit is involved in
memory formation (Cheli et al., 2006) and is phosphory-
lated after training in mice. However, NMDA NR1
phosphorylation is not observed in Akt1(/) animals.
Therefore, Dr Franke concluded that Akt signaling is
important in learning and higher brain function.
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14. PSYCHIATRIC GENETICS AND
PHARMACOTHERAPY
Reported by Eric J. Vallender
One of the promises of psychiatric genetics is for the
development of efficacious treatments for disease. While
much of the efforts in the field still revolve around
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identification of the genes and genetic networks under-
lying psychiatric disease, an emerging field is focused on
the genetic variation underlying the differential
responses to treatment of disease. This has focused
primarily on varying efficacy rates of pharmacothera-
pies, but can be extended to other treatment options
as well. The focus of the ‘‘Psychiatric Genetics and
Pharmacotherapy’’ session was to highlight the work
being done in the field and to offer insight into study
design and interpretation moving forward.
Schizophrenia: From Gene Arrays to Novel Drug
Targets: Dr. Catherine Winchester presented a rodent
model of schizophrenia and its uses to develop novel
drugs for treatment. The model, which uses rats treated
with chronic intermittent phencyclidine (PCP), mirrors
the cognitive deficits that are a hallmark of schizo-
phrenia [Morris et al., 2005]. Specifically, schizophrenic
patients tend to present with deficits in attention,
cognitive flexibility, and goal setting behaviors. These
behaviors are correlated with prefrontal cortex hypo-
function and can be behaviorally modeled in the rodents
[Cochran et al., 2003].
Using RNA isolated from the prefrontal cortex of the
rats, the transcriptome of the schizophrenia model was
interrogated. The results were encouraging with genes
and pathways previously implicated in human schizo-
phrenia showing differential expression and with 20% of
the differentially regulated transcripts in rats mapping
to syntenic regions previously showing an association in
humans. Additional novel pathways were identified that
may serve as potential drug targets and collaborations
are underway to develop these opportunities. This will
be additionally aided through the development of a gene
array focused specifically on genes implicated in the
schizophrenic phenotype. Initial studies using cloza-
pine, an antipsychotic commonly used in the treatment
of schizophrenia, failed to show a reversal in the
transcriptome of the rats. This parallels observations
in patients regarding treatment efficacy related to
cognitive aspects of the disease.
During discussion several other uses of the data were
approached. It was stressed that the rat PCP model
focuses on the cognitive deficits associated with schizo-
phrenia and that many of the current anti-psychotics,
including clozapine, are limited in their efficacy in
treating this aspect of the disease. At this point other
antipsychotics had not been modeled in the system, but
the framework was there for future studies. While it was
acknowledged that the PCP rat model does not model
the dopaminergic perturbations seen in human
patients, it was noted that it does reflect the cognitive
deficits that are a major aspect of the disease. Another
question arose as to the possible use of any of these
differentially regulated genes in the prefrontal cortex as
early diagnostic indicators for schizophrenia; work
which will require future studies. It was also observed
that the directionality of expression differences in the
rat and human were not always the same, leading the
researchers to focus on disruptions in pathways that
may represent the disease state rather than focus on
individual genes.
Pharmacogenetics of Treatments Outcome and Adverse
Effects in the STAR*D Cohort. Research into the
association between genetic variation and treatment
effects in the STAR*D cohort of individuals with major
depression was presented by Dr. Francis McMahon. The
STAR*D cohort of individuals with major depressive
disorder (MDD) underwent standard clinical treatment
wherein they were treated with the antidepressant
selective serotonin reuptake inhibitor (SSRI) citalopram
when appropriate. They were then evaluated for remis-
sion of symptoms, response to pharmacological inter-
vention, and tolerance of the drug. These individuals
were then tested for genotypes at 68 candidate genes
chosen for previous association with mood disorder,
antidepressant outcome, or known functional variation
using a split-sample, test/replication design.
Several positive associations have come from this data
including an association between HTR2A and non-
responsiveness to citalopram (McMahon et al., 2006),
GRIK4 and both remission and response (Paddock et al.,
2007), and BCL2 and response. (Non-responsiveness
was chosen as the most appropriate measure for
comparison of treatment in order to exclude patients
showing a placebo effect.) These genes also showed
interactions which resulted in lessened non-responsive-
ness to treatment. Additionally, the cohort was able to
replicate findings of an association between FKBP5 and
remission rates.
A further study showed an association between
the serotonin transporter promoter polymorphism
(5HTTLPR) and tolerability but not treatment outcome
(Hu et al., 2007). This is noteworthy for several reasons.
First, the effect was seen between the high expression
LA allele (associated with greater tolerance) compared to
the low expression S and LG alleles (associated with
lesser tolerance); a dichotomous S vs. L comparison
failed to identify association. Secondly, the effect was
associated with tolerability rather than response. It is
possible that differences seen in previous studies
attempting to associate 5HTTLPR with antidepressant
response are a result of either the lack of differentiation
between L alleles or differences in the way drug-
intolerant patients are treated in the data analysis.
Studies were also undertaken to look for genetic
associations with emergent suicidal ideation during
anti-depressant treatment. These studies found an
association with GRIA3 and GRIK2 in the STAR*D
cohort (Laje et al., 2007). A follow-up whole genome
association study also identified IL28R and PAPLN as
potentially associated with treatment emergent suicidal
thinking.
During discussion it was noted that while promising,
these pharmacogenetic studies will require greater
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numbers of markers to be fully informative in the future.
It was also observed that compliance was not strictly
measured in this cohort, for instance by pill counting or
through drug levels in the blood, though patients were
asked about adherence to medication. Non-compliance
was, and is, a potential confound for many pharmaco-
genetic studies. A final comment noted the overlap
between the genes associated with suicidal ideation
developing from treatment and those associated with
bipolar disorder. While the connection remains unclear,
there are reasons to hypothesize an overlap between
these gene sets.
Genetic Association Data from GENDEP, a Multicentre
European Study
Dr. Katherine Aitchison presented progress on the
genetic association analysis of response to anti-
depressants in the multicentre, European Commission
funded, study GENDEP (‘‘Genome-based Therapeutic
Drugs for Depression’’). This study recruited indivi-
duals of white European ancestry with depression
diagnosed using a research diagnostic interview. Indi-
viduals with certain comorbidities, including bipolar
disorder and schizophrenia, were excluded. Subjects
were treated with either nortriptyline (a pronoradre-
nergic antidepressant for which the primary target
is the norepinephrine transporter) or escitalopram,
the S-enantiomer of the SSRI citalopram (for
which the primary neuronal target is the serotonin
transporter).
Patient response was measured serially post-baseline
using three different measures of depression (the
HDRS, the MADRS, and the BDI), comprising a total
of 48 questions. Factor analysis on this data resulted in
three factors: mood and anxiety, cognitive symptoms,
and neurovegetative symptoms [Uher et al., 2007].
While both groups treated with nortriptyline and
escitalopram showed substantial improvement over
the twelve week period of evaluation, preliminary
analyses showed a greater improvement in neuro-
vegetative symptoms in the group treated with the
pronoradrenergic while the improvement in mood and
anxiety was greater in the group treated with the
proserotonergic.
Variation in twelve candidate genes was tested for
association with treatment response. In particular,
5HTTLPR genotype was associated with response as
measured by the mood and anxiety factor for subjects
treated with escitalopram, but not with nortriptyline
response or other response factors. Homozygote carriers
of the low expressing S allele responded more poorly
than those in the L/S and L/L genotypic groups. A
preliminary analysis using the rs25531 SNP further
refines the groups.
Future studies in the system will include stratifica-
tion analysis as well as incorporating data on adverse
effects of the drugs and patterns response in terms of
time course. In the discussion, continuing analyses
including the interaction between 5HTTLPR and life
events were also mentioned.
Whole Genome Association Analysis of Treatment
Response in Schizophrenia. A whole genome associa-
tion study of schizophrenia treatment response was
presented by Dr. Anil Malhotra. The study began as
a whole genome association study for schizophrenia
using 178 cases and 144 controls. All individuals
were recruited and evaluated at a single site and
were matched for ethnicity, general environment,
and socioeconomic background. This study identified
an association between the cytokine-related genes
CSF2RA and IL3RA and schizophrenia spectrum dis-
orders [Lencz et al., 2007]. Resequencing studies
subsequently showed both common intronic haplotypes
as well as rare missense variations associating with the
disease.
Patients were clinically assessed and treated either
using the antipsychotic clozapine or using a non-
clozapine based treatment strategy. Traditionally clo-
zapine has been reserved for patients who fail to show a
response to prior treatment; as such the clozapine
treated group was used as a proxy for non-responsive-
ness to schizophrenia medications while the non-
clozapine treated group proxied responsiveness. A
whole genome association study comparing the 62 non-
responsive patients to the 110 responsive patients
identified SNPs in 5 genes differentially distributed
between the groups. Several of these genes had a
‘‘biological plausibility’’ for a difference in treatment
efficacy of schizophrenia.
The importance of first episode studies was high-
lighted during discussion. In particular it was relevant
to understand prior treatment histories and the effects
that may have on the pharmacogenetic association
studies. Similarly the importance of a priori assigned
response criteria was stressed. The findings presented,
however, offered a first look at the methods that can
hope to be employed and yielded promising initial
results. Future studies on the response of first episode
schizophrenia subjects to additional antipsychotics will
incorporate these findings.
Alcohol Dependence Associated SNPs in Genes Encod-
ing GABA-A Subunits Predict Post-Treatment Drinking
Behavior in Project MATCH. Genetic variation has also
been shown to influences the effectiveness of psychoso-
cial treatment. Dr. Jonathan Covault presented on the
effects of genetic polymorphism in the efficacy of
treatment of alcoholism in Project MATCH. Project
MATCH is a multi-center clinical trial of Cognitive
Behavioral Therapy (CBT), Motivational Enhancement
Therapy (MET) and Twelve Step Facilitation (TSF) as
treatment therapies for alcoholism. Levels of drinking
were measured during the treatment period (12 weeks)
as well as during post-treatment (12 months). During
the original study, DNA was collected, but has remained
unanalyzed until now.
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Initial genetic association studies have focused on the
GABA-A receptors. The Collaborative Study on the
Genetics of Alcoholism (COGA) initially identified an
association between GABRA2 and alcoholic behavior
that was later widely replicated [Edenberg et al. 2004].
In the Project MATCH cohort there was also association
seen with alcohol dependence and GABRG1, located
immediately telomeric of GABRA2 on 4p (Covault et al.,
2007). Haplotypes of GABRA2 and GABRG1 were in
partial linkage disequilibrium in the sample resulting in
the inability to resolve risk associated with each
separately.
Individuals harboring the alleles of GABRA2/
GABRG1 associated with a greater proclivity towards
alcohol dependence did not show a significant difference
in treatment efficacy among the three psychosocial
treatments under study, however individuals with the
low-risk alleles at the genes showed variation in treat-
ment response with TSF having more favorable out-
comes compared to MET or CBT. This may indicate that
those individuals with high-risk alleles are better candi-
dates for pharmacotherapy while those with low-risk
alleles are better candidates for psychosocial therapy.
The differences between GABRA2 and GABRG1 were
briefly discussed; specifically that GABRA2 was ubiqui-
tously expressed while GABRG1 had a much more
restricted expression pattern specific to neurons. This
may have implications for interpreting the association
results. Also focus turned to how pharmacotherapy, in
particular with benzodiazepines, would affect response
to psychosocial treatments. At the time of the study
pharmacotherapy was excluded, but it is a reasonable
hypothesis that concurrent treatment with pharmaco-
logical agents would affect the differences seen in
psychosocial therapy efficacies.
Pharmacogenetics of Antidepressants in Mood Disorder:
A Proposal for Methodological Guidelines. Dr. Alessan-
dro Serretti concluded the session with a discourse on
the methodological procedures and controls needed to
ensure high quality, meaningful results in studies of
mood disorder pharmacogenetics. As pharmacogenetic
studies of mood disorders have proliferated so have
differences in methodologies and heterogeneities in
approaches and samples. A summary of the issues and
variables surrounding these studies was presented to
compliment published work (Serretti et al., 2007).
Numerous methodological issues requiring attention
in the literature were raised generally falling into the
categories of socio-demographic differences, clinical,
treatment, and assessment issues, and statistical
and genetic issues. Socio-demographic, statistical, and
genetic issues transcend pharmacogenetic studies and
have been shown to be important in numerous associa-
tion studies. Control for age, sex, ethnicity, or socio-
economic status should be de rigueur for association
studies, but the difficulty in obtaining the number of
patients required to gain power may have lead to
compromises here. Genetically, it is necessary to
account for all genetic variants and for partial and
unspecific effects. Statistically it is important that
power analyses be employed, that the same population
not be employed for repeated analyses, and that
negative findings are reported to properly correct for
multiple testing biases. Equally important is for the
statistical methods used to accurately reflect the under-
lying model, with both simple univariate analyses
required as well as more complex multivariate and
non-parametric models.
Issues in clinical, treatment, and assessment meth-
odologies are more specific to psychiatric studies in
general and pharmacogenetic studies in particular.
Patients with comorbid disorders need to be excluded
and severity and persistence of symptoms made clear.
The base clinical indications also need to be made clear
for future comparisons to be valid. It is of particular
importance in pharmacogenetic studies that patients be
first episode or drug naı̈ve, and when not that this be
taken into consideration in analysis as number and
length of episodes may strongly affect outcome. During
treatment it is also important that compliance be closely
monitored and that concomitant drugs be avoided or
controlled for (including a washout period before
commencement of the study). When comparing drugs,
it is also important for differences in mechanisms of
action to be considered. Assessment similarly must be
standardized, including studies of side effects, with both
frequent early assessments as well as long term studies.
Unsurprisingly, the discussion focused on how these
proposals could be implemented practically. Questions
were raised as to the numbers of individuals necessary
to achieve power given the large number of variables
and the limitations and assets of existing studies.
Certainly many subjects will be needed, but it will vary
depending on the study. In the meantime, it will be
important to minimize heterogeneity wherever possible
and to include as much detail as possible in areas where
variation among subjects cannot be avoided. It was also
noted that there are publication difficulties as regards to
introducing new statistical methodologies and publish-
ing negative results. While these deficits certainly exist,
they need to be challenged by the community. In
particular, while homogeneity across studies is impor-
tant, if there are deficits that can be addressed they
should be. Current studies simply cannot address all of
the concerns raised but as the field progresses control-
ling for these factors will gain in importance.
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15. NEW BIOINFORMATIC AND
COMPUTATIONAL METHODS
Reported by Robert Karlsson
This session consisted of nine short presentations of new
tools in bioinformatics and statistical analysis. Each
speaker also had a poster at the conference, and was
available in a poster viewing session following immedi-
ately after the presentation, so interested audience
members could find out more about the methods than
the 10-minute presentations allowed for in an informal
setting. The session was divided into three categories of
methods, the first of which was called ‘‘Tools for genome-
wide association studies’’.
The first speaker in this part of the session was
Katherine Todd-Brown, presenting the tools PLINK (by
Shaun Purcell), gPLINK, and Haploview for managing,
analyzing, and visualizing whole genome association
study data. PLINK is the major analysis and data
management component, and comes with an ever-
growing array of statistical methods. gPLINK is a
graphical user interface to PLINK, facilitating the usage
of PLINK by giving menu choices for the available
actions and analyses, and then sending the user’s intent
to PLINK (which can run on a different computer or
even a compute cluster) for execution. Haploview is a
tool that integrates with gPLINK and provides visuali-
zation of linkage disequilibrium structure in association
samples, as well as several analysis methods. The
software packages are open source (GPL), runs on most
major platforms (Windows, Mac, Linux), and are freely
available from http://pngu.mgh.harvard.edu/purcell/
plink (PLINK, gPLINK) and http://www.broad.
mit.edu/mpg/haploview (Haploview).
Next was Manuel Ferreira, presenting two new
algorithms for analyzing gene-gene and SNP-SNP
interactions in whole genome association study data.
The methods have been tested on the STEP-BD and
WTCCC datasets for bipolar disorder. No interactions
remained significant after correcting for multiple test-
ing, but according to the authors a few interesting
findings were made nonetheless, considering the geno-
mic location of the top-ranked SNPs. Both algorithms
are included in the PLINK software package.
Final speaker in this section was Lauren Weiss,
presenting a new program called COPPER, used for
analysis of copy number polymorphisms in GWAS data.
The method has been tested on autism and bipolar
datasets and identified several copy number polymorph-
isms with a possible influence on disease susceptibility.
Validation of these findings is currently ongoing.
COPPER does not yet have a public website, so for more
information about this method contact Lauren at
laweiss@chgr.mgh.harvard.edu.
The next category of methods was called ‘‘Bioinfor-
matic tools’’. First was Patrick Sullivan, presenting
three bioinformatic tools for use in psychiatric genetics:
TAMAL, SNP Annotations, and SLEP. TAMAL stands
for ‘‘Technology And Money Are Limiting’’, and is used to
aid in the selection of representative SNPs for a set of
candidate genes. SLEP (Sullivan Lab Evidence Project)
is a search engine for results from genome-wide
association and linkage studies in psychiatric genetics.
The tools are available online at http://neoref.ils.
unc.edu/tamal/ (TAMAL) and https://slep. unc.edu/
evidence/ (SNP annotations and SLEP).
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Next was Michael Galsworthy, presenting the tools
MEDSUM and BITOLA. MEDSUM is used to summar-
ize information from Pubmed and create profiles for both
authors and other search terms. BITOLA is an auto-
mated literature search tool, which looks for links
between genes, compounds and diseases in several
databases. The aim is to discover interesting and
previously not examined hypotheses in the links. The
tools are available online at http://webtools.mf.uni-lj.si/.
Lars Bertram presented the SchizophreniaGene
database. This is a continuously updated collection of
results from association studies in schizophrenia, both
original studies and meta-analyses. The database can be
reached at http://www.szgene.org/.
The final presentation in the bioinformatics section
was by Melvin McInnis, representing the National
Center for Integrative Biomedical Informatics (NCBI).
The NCIBI aims to facilitate research in complex
diseases by making large amounts of information and
tools from different sources available to researchers in a
consistent framework. The tools provided by the NCIBI
are available online at http://www.ncibi.org/.
The third and final category of methods in this session
was called ‘‘Statistical methods’’. First speaker here was
Jason Moore, presenting the Multifactor Dimensional-
ity Reduction algorithm (MDR). MDR can be used in the
search of epistasis effects in genetic association data.
The algorithm works by transforming the data in a way
that makes epistatic effects detectable by other methods
such as naive Bayes and logistic regression in the
transformed data. More information about the algo-
rithm and download links can be found at http://
www.epistasis.org/ and http://www.multifactordimen-
sionalityreduction.org/.
Final speaker of the session was Cathryn Lewis,
presenting a meta-analysis of genome-wide linkage
studies in schizophrenia. Her study used the Genome
Search Meta-Analysis (GMSA) algorithm, which divides
the genome into bins of equal length and compounds
scores from several linkage studies over these bins in
order to increase the power to detect linkage. GMSA was
applied to 31 genome-wide linkage scans to produce a
map of the most interesting regions for linkage in
schizophrenia. The tool used in the analysis can be
downloaded from http://www.kcl.ac.uk/depsta/memoge/
gsma/.
16. COPY NUMBER VARIATION: IMPLICATION
FOR PSYCHIATRIC DISEASE
Reported by Srijan Sen and Sandra Villafuerte
The following presentations took place:
1) Widespread human structural genomic variation:
what have we learned over the past 3 years? Presenter:
Charles Lee. Harvard Medical School, Pathology,
Boston, USA. Dr. Lee started with a brief overview on
the current knowledge on copy number variation (CNV),
properties and associations with common diseases.
CNVs are deletions and duplications of DNA segments
larger than 1 kb and up to several Mb in size that are
present in variable copy number. In 2004, two studies
reported the wide-spread presence of CNVs in healthy
individuals (Iafrate et al., 2004; Sebat et al., 2004). He
referred to a recent publication (Redon et al., 2006) and
online databases that provide a catalog for CNVs: 12% of
the human genome represent discrete CNV regions
(CNVRs) and there are about 70 CNVs per individual. A
large percentage of CNVs are localized both in genes
that encode products that interact with the environment
and in genes associated with Mendelian or complex
disorders. Currently, 12 association studies have been
reported between CNVs and common diseases. The
Structural Genomic Variation project is screening 40
subjects for CNVs at a high resolution of 500 bp in order
to provide to the scientific community with absolute
CNVs for association studies. 8000 CNVs from healthy
individuals are currently listed in the Database of
Genomic Variants (http://projects.tcag.ca/variation).
Only a fraction have been independently verified and
the frequency of certain CNVs can vary among ethnic
populations. For clinical phenotypes it is important to
map, characterize and catalog all CNVs and compared
them to few reference genomes to obtain absolute copy
number information. The size, the number and type of
genes that lie within CNVs are clinically important.
Additional considerations include the characterization
of CNVs in other species to explore the possibility of
specific sequence motifs present in CNVs. Across
primates there is homology of 60–70%. CNVs are
generally stable over few generations. CNVs can affect
gene expression levels by either altering the actual
dosage of a particular gene or indirectly affect regula-
tory elements. The impact of CNVs on clinical diagnosis
may be clear for some CNVs while for others further
assessment may be necessary to clarify their clinical
relevance. About 20% of CNVRs identified so far are not
covered by the newest generation of genome-wide arrays
such as Affymetrix or Illumina probes.
2) Recurrent Genome Structural Variation and Cogni-
tive deficits. Presenter: Evan Eichler. University of
Washington and HHMI, Genome Sciences, Seattle,
USA. Dr. Eichler described a study aiming to character-
ize duplicated/deleted regions associated with mental
retardation (MR) and developmental delay. Duplicated
sequences account for 4–5% of the genome and can
‘‘trick’’ normal meiotic process resulting in altered copy
number variation. Several duplication syndromes
include some kind of mental retardation. The study
focus on 130 genomic regions as potential candidates for
undescribed genomic disorders associated with MR.
They compare 530 children with idiopathic MR and
other cognitive deficits that present karyotype abnorm-
alities vs. normal controls. A deletion on chromosome
17q was present in four MR individuals but not in 1000
controls. To date, 21 deletions have been found in MR
children. The Decode group found that this region is
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inverted in 70% of Europeans, increased fertility and is
under positive selection. All children with the deletion
have a parent with the selected inversion, so the allele
resulting in increased fecundity has the downside of
predisposing to carry the deletion onto the next genera-
tion.
3) A large-scale study of de Novo copy number variation
in Autism. Presenter: Jonathan Sebat. Cold Spring
Harbor Laboratory, Cold Spring Harbor, USA. Dr. Sebat
started with a rationale on the implication of CNVs in
Autism. Various studies have implicated structural
variants across the genome in Autism. Microscopic
abnormalities have been identified in 5–7% of autistic
patients. The baseline mutation rate of CNVs is higher
than SNPs and confers 100 fold higher risk for disease
occurrence. CNVs in Mendelian diseases are rare
(1/10,000). However, in complex traits, as in Autism,
CNVs are present at much higher rate (1/200 subjects if
50 genes are involved in the susceptibility). Compara-
tive genomic hybridization (CGH) was performed on a
large sample of families with one (simplex) or multiple
(multiplex) offspring with idiopathic autism spectrum
disorders in order to detect CNVs in patients and
unaffected subjects that are not present in their parents,
searching for sporadic or de novo CNVs. A deleted region
of 30 genes, including oxytocin and vasopressin, was
identified in a simplex patient diagnosed with Asperger
syndrome. Between 10 and 15 de novo CNVs have been
confirmed in these subjects. All CNVs larger than 4 Mb
have been previously identified, while smaller CNVs are
de novo. In summary this large scale study has found
10 % of sporadic cases have de novo CNVs (25% of these
in female subjects). 9/10 de novo CNVs found in this
study are clinically relevant. The presence of de novo
CNVs was significantly (p¼ 0.0005) more frequent in
patients (14/195) than in controls (2/196). The rate of
de novo mutations identified in this study is an under-
estimate, maybe due to the limited resolution of genome
microarray scans.
4) CNVs at a bipolar disorder locus on 8q24. Presenter:
Margit Burmeister. Molecular & Behavioral Neu-
roscience Institute, University of Michigan, Ann Arbor,
Michigan, USA. Dr. Burmeister described the detection
and analyses of CNVs in a bipolar locus on chromosome
8q24. In an attempt to refine this region, 1536 SNPs
were selected for genotyping in 3512 individuals from
734 families with Bipolar Disorder (NIMH, Hopkins)
using Illumina Golden Gate. Mendelian errors and
deviation from Hardy-Weinberg equilibrium were iden-
tified for 14 consecutive SNPs that mapped to a 182 kb
CNV region listed as variation_0337 in the Database of
Genomic Variations. The presence or absence of the
deletion was tested by PCR, indicating that the deletion
was present in carriers from all families with Mendelian
errors. To test association between this CNV and Bipolar
disorder, an algorithm was developed by a collaborator,
Sebastian Zoellner, to use Illumina SNP genotype
intensity data to infer carrier status for the deletion/
insertion. This EM algorithm models the intensity
distribution for each SNP in the deletion into two
groups, heterozygous for the deletion, or absence of the
deletion. The algorithm does not call for homozygotes for
the deletion. All 3512 individuals were unambiguously
scored, 1 individual homozygous for CNV (per PCR), 172
deletion carriers and 3339 not deleted. 4.4% of carriers
for the deletion were among unrelated individuals. The
association was tested using the software for Linkage
and Association Modeling in Pedigrees (LAMP) [Li et al.,
2005] to jointly estimate both genotype count in cases
and controls and transmission frequency of alleles. The
CNV 0337 was not associated with Bipolar disorder in
this sample. This algorithm, developed to score pre-
sence/absence of known CNVs, will be available shortly
as a useful tool to measure CNVs from GoldenGate (and
also GWA) SNP chips directly.
Discussion
The audience expressed interest on the experience these
investigators had with the study of CNVs, the impact
they may have on psychiatric diseases, considerations
for future study designs including methodological issues
and relevance of CNVs compared to SNPs in disease or
trait susceptibility. Some issues raised in the discussion
included:
1. It was suggested that the NIMH has a large group of
subjects with psychiatric data which would be good
control subjects, but that companies need to create
platforms to cover CNVs genotyping.
2. The need exists for obtaining formal consent to re-
contact individuals for in depth further phenotyping.
3. There may be an accumulation of many rare alleles as
will be found in CNV studies and these can cause
common disease rather than few common variants.
4. A strong linkage signal, does not speak against CNVs
as a plausible cause if the CNV is not de novo. It is more
likely that a mixed model may explain the signal.
5. The majority of the identified mutations in Autism
are not recurrent, but are unique; about 6 are found
multiple times. There is a need for large sample size to
obtain appropriate characterization of these mutations.
6. It is true that simplex/multiplex families are not
clearly distinguishable; but it is important to enrich
cohorts for simplex families to increase the identification
of de novo variants.
7. If we discard SNPs data that violate Hardy Weinberg
Equilibrium, we may be discarding SNPs that are
relevant to CNVs. David Altshuler (MIT) developed a
program to score SNPs for CNV signatures.
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17. GENE EXPRESSION STUDIES
Reported by James Crowley
Modern molecular biological techniques have increased
our understanding of the links between gene expression,
protein function and behavior. For example, GAD67,
RGS4, DTNBP1, NRG1, and GABRAB2 show expres-
sion alterations in the postmortem brain of subjects with
schizophrenia, and these genes have also been impli-
cated as schizophrenia susceptibility genes (Chen et al.,
2004; Volk et al., 2000; Straub et al., 2002; Stefansson et
al., 2002; Petryshen et al., 2005; Lo et al., 2004). Gene
expression profiling by DNA microarray has proven to
be a powerful method to uncover relationships between
gene expression alterations and psychiatric disorders.
This year’s WCPG meeting featured a series of talks by
investigators examining the association between dis-
ease status and changes in gene expression and protein
function.
Dr. Melanie Carless from the Southwest Foundation
for Biomedical Research (San Antonio, TX) spoke on
‘‘Transcriptional profiling for identification of cis-regu-
lated genes involved in complex brain-related disor-
ders’’. The genetic determinants of complex brain-
related disorders such as schizophrenia, depression,
and Alzheimer’s disease remain poorly understood,
partly due to an incomplete understanding of normal
brain structure and function. Carless and performed
genomewide transcriptional profiling in a population of
1,240 individuals in the San Antonio Family Heart
Study (SAFHS) using lymphoblast RNA. A total of
20,000 transcripts were significantly detected, with
16,829 of these being significantly heritable. There were
nearly 3,000 autosomal cis-acting QTLs: linkage
evidence for variation at the transcripts genomic
location that influences expression levels. Among these
cis-regulated transcripts were a number of genes
previously implicated in various brain-related mental
disorders, including NRG1 (cis-LOD¼ 15.8), DISC1 (cis-
LOD¼ 3.9) and DTNBP1 (cis-LOD¼2.1). They rese-
quenced 2kb of the proximal promoter region of these
genes in a founder population to identify regulatory
variants influencing expression levels, with genotyping
efforts expanded to the remaining SAFHS population.
To date, they have identified ten polymorphisms (three
novel) within the promoter region of NRG1, ten
polymorphisms (five novel) within DTNBP1 and nine
polymorphisms (three novel) within DISC1.
In sum, significant associations were detected
between promoter variants and expression levels of
psychiatrically important candidate genes. Identifica-
tion of functional regulatory variants within these genes
will give further insight into how they influence
psychiatric disorders.
An audience member asked what the minor allele
frequencies (MAFs) were for the proximal promoter
region SNPs identified by resequencing. Dr. Carless said
that, in general, the previously identified SNPs ranged
from 0.3–0.5 MAF, while the novel SNPs were pre-
dominantly below 0.05 MAF. A second questioner asked
if a proteomic analysis would be performed to comple-
ment these data. Dr. Carless reported that this will
indeed occur and that they have plasma frozen already.
The final questioner asked if there were any future plans
to look at methylation- Dr. Carless said they were not
planning to examine this.
Dr. Herb Lachman from the Albert Einstein College of
Medicine (New York, NY) presented ‘‘Identification of
regulatory domains in schizophrenia and bipolar dis-
order candidate genes using chromatin immunoprecipi-
tation and tiled microarrays (CHIP-CHIP)’’. A number
of genes have been identified as potential candidates
underlying schizophrenia (SZ) and bipolar disorder (BD)
susceptibility. However, it has been exceedingly difficult
to identify disease associated allelic variants. One
reason is that responsible functional alleles may exist
in unidentified regulatory domains, which are difficult
to characterize. However, in recent years it has become
feasible to blindly screen genes in their entirety,
including large amounts of flanking DNA, for regulatory
domains using microarray-based approaches, such as
ChIP-chip. Lachman and colleagues immunoprecipi-
tated chromatin derived from fetal brain using an
antibody against histone H3 acetylated at lys9 and
lys14 (H3K9/14Ac), a chromatin marker for promoters
and some enhancers, and an antibody against histone
H3 monomethylated at lys4 (H3K4me1), a marker for
enhancers. These were used as probes for DNA micro-
arrays containing the entire sequence of NRG1,
DTNBP1, DISC1, including flanking regions, as well
as 3 megabases of DNA from the region on 22q11 deleted
Rapporteur Reports 267
in VCFS. The H3K9/14Ac ChIP-chip experiment clearly
identified the promoters active in fetal brain in each of
the candidate genes including four found in the complex
NRG1 locus. Putative enhancers in several candidate
genes were found as well. Dozens of SNPs are known to
exist in these regions, some of which will be analyzed
as potential disease associated variants. The results
indicated that ChIP-chip can be used to map regulatory
domains in SZ and BD candidate genes, thereby
targeting discrete regions for mutation detection analy-
sis that may identify novel candidate alleles underlying
disease susceptibility.
An audience member asked if any adult tissues were
examined to determine if the same promoters were
active in the human brain. Dr. Lachman replied that
they have not yet performed ChIP-chip in adult tissues,
but that electrophoretic mobility shift assays (EMSAs)
were currently being undertaken in adult tissues.
Dr. Sibylle Schwab from the University of Western
Australia (Nedlands, Australia) presented an ‘‘Expres-
sion study of DTNBP1 in lymphoblastoid cell lines from
a family sample with evidence for association’’. DNA
sequence variants (SNPs) located in the dystrobrevin
binding protein 1 gene (DTNBP1, dysbindin) gene have
been shown to be associated with schizophrenia. How-
ever, association is restricted to SNPs in intronic region
and no obvious functional SNPs have been identified.
Multiple splice transcripts with introns have been
identified for dysbindin. Due to the absence of an
association with a coding SNP the authors investigated
if susceptibility to schizophrenia may be due to altered
gene expression of dysbindin. Total RNA extracted from
lymphoblast cell-lines of affected individuals was ampli-
fied by RT-PCR. Quantitative real time RT-PCR using
Taqman probes spanning exon 5/6 and exon 9/10 of
DTNBP1 were used to quantify the expression. Relative
expression of dysbindin was normalized with two
housekeeping genes (GUSB and GAPDH). The Delta-
DeltaCt method was used for the analysis of relative
expression. Splice variants were compared to those
found in RNA from post mortem brain samples. The
results indicated that dysbindin was alternatively
spliced in lymphoblasts. Using primers located in exon
1 and 6 of the gene, Schwab and colleagues identified a
splice variant missing exon 2 and 3. Dysbindin splice
variants as detected in RNA from post mortem brain
samples revealed the same pattern. In addition, dysbin-
din mRNA expression was increased in RNA isolated
from lymphoblasts from patients with schizophrenia
compared to controls. In conclusion, the authors
obtained evidence for the existence of dysbindin splice
variants in lymphocytes and potential differential
regulation of these variants in schizophrenia.
Dr. Schwab was asked whether the increased dysbin-
din mRNA seen in lymphoblasts from schizophrenis
patients translates to increased levels of dysbindin
protein. She indicated that her lab is currently perform-
ing these experiments.
Dr. James Sutcliffe from Vanderbilt University
(Nashville, TN) spoke on ‘‘Autism-associated serotonin
transporter variants confer gain of function phenotypes
arising through distinct mechanisms’’. The serotonin
transporter (SERT) is responsible for 5-HT inactivation
in the CNS and peripherally. SERT is implicated in
multiple brain disorders, including obsessive-compul-
sive disorder (OCD), and autism. Sutcliffe and collea-
gues recently identified multiple autism-associated
variants in the SERT gene (SLC6A4), including four
rare coding variants (Gly56Ala, Ile425Leu, Phe465Leu
and Leu550Val). These variants are associated with
more severe OC behaviors in carriers with autism.
Other studies found Ile425Val in subjects with Asper-
ger’s syndrome and OCD. The authors previously
showed that Gly56Ala shows elevated basal activity
and insensitivity to PKG/p38MAPK regulation. In this
study, variant SERTs were examined for altered 5HT
uptake, surface and total SERT binding and signaling
properties through transfection in HeLa cells. The
results indicated that Ile425Leu, Ile425Val, Phe465-
Leu, and Leu550Val encoded SERT display elevated
basal 5HT uptake, resulting from an elevated Vmax.
Contrasting Gly56Ala, which shows elevated transport
without changes in surface density, the other variants
display elevated surface expression that parallels
changes in 5HT uptake, suggesting changes in consti-
tutive transporter trafficking. Additionally, Ile425Leu,
Ile425Val, Phe465Leu and Leu550Val respond to PKG,
p38MAPK and PKC stimulation similar to wild-type
SERT.
These studies indicate two distinct mechanisms by
which these variants result in increased 5HT transport,
suggesting that inappropriately elevated 5HT clearance
and diminished extracellular 5-HT mediated by SERT
may be critical risk factors for autism and OCD. In terms
of future directions, Dr. Sutcliffe indicated that his group
is pursing the hypothesis that loci for other proteins
regulating SERT harbor autism-associated risk factors.
Dr. Richard Straub from the National Institutes of
Mental Health (Bethesda, MD) discussed ‘‘The BLOC-1
protein dysbindin modulates dopamine D2 receptor
internalization and signaling but not D1 internalization
in rat primary neurons, human neuroblastoma cells,
and human B lymphoblasts’’. Variation in DTNBP1
influences expression, cognition and schizophrenia risk.
Expression in schizophrenia is deficient, but the
mechanisms by which this contributes to pathogenesis
and symptomatology are unknown. One function of
dysbindin involves BLOC-1, an endosomal trafficking
complex that includes proteins from MUTED and
BLOC1S2, genes that the authors have also found to
increase risk. Elevated dopamine D2 receptor (DRD2)
density has been observed in schizophrenia and DRD2
antagonism appears important to therapeutics, so they
studied dysbindin effects on dopamine signaling. The
authors transfected siRNA for DTNBP1 or MUTED into
rat primary cortical neurons, human SH-SY5Y neuro-
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blastoma cells, and human B lymphoblasts. These cells
were then examined for cell surface levels of DRD2 and
DRD1 using flow cytometric quantitation, as well as
CREB phosphorylation, an intracellular signal down-
stream of DRD2. They found that DTNBP1 siRNA
decreased dysbindin protein, increased DRD2, and
completely blocked dopamine-induced DRD2 internali-
zation. MUTED siRNA reduced dysbindin and produced
similar effects. DRD1 was unchanged, as were basal-
and dopamine-induced internalization. Reduction of
CREB phosphorylation by the DRD2 agonist quinpirole
was enhanced by dysbindin down-regulation. Haloper-
idol blocked this effect, indicating that the CREB signal
required DRD2 stimulation. In conclusion, the authors
noted that this was the first demonstration of a
functional effect of a schizophrenia susceptibility gene
on DRD2 signaling, a pathway long implicated in the
illness. They also proposed a molecular mechanism
in which DTNBP1 risk alleles down-regulate dys-
bindin, inhibiting BLOC-1 trafficking of DRD2 towards
degradation. Upregulation of DRD2, but not DRD1,
contributes to the imbalances in dopaminergic neuro-
transmission characteristic of schizophrenia. Their
observation of statistical epistasis between COMT and
DTNBP1 that impairs cognition and increases risk
suggests that DRD2 upregulation induced by dysbindin
deficiency may be particularly detrimental for COMT
Met158Met individuals, due to their elevated cortical
dopamine.
An audience member asked whether variation in the
dysbindin gene has been associated with risk of tardive
dyskinesia, which some suspect results from upregula-
tion of D2 dopamine receptors. Dr. Straub replied that,
to his knowledge, this has not been looked at.
In the general panel discussion that followed these
presentations, a series of questions related to lympho-
blastoid cell lines were raised. The first related to how
much variability in gene expression is seen over time in
replicates of these cell lines. No member of the panel or
audience was aware of a study that had examined this
particular question in detail. The second question asked
if substantial differences are seen in the gene expression
profiles of transformed lymphocytes versus fresh lym-
phocytes. Again, no member of the panel or audience
was aware of a study that had examined this question in
detail. A final question was how well the gene expression
profile of human lymphoblastoid cell lines relates to that
of human brain. A panel member indicated that a study
designed to answer this question is currently being
performed in baboons, comparing the expression profile
of lymphocytes with that of a number of distinct brain
regions.
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18. SEX CHROMOSOME ANEUPLOIDIES
AND THE SEX CHROMOSOMES IN
PSYCHIATRIC DISORDERS
Reported by Neetha N. Vijayan
The World Congress on Psychiatric Genetics 2007, held
at New York in October, had a very interesting and sti-
mulating session on sex chromosomes and their influence
in psychiatric disorders. This enlightening session was
chaired by T.J.Crow from Oxford University and had
Lynn Delisi from New York University School of Medi-
cine as discussion moderator, with five presenters in
total.
David Skuse from The Institute of Child Health, UK,
presented his observations on the impact of human X
linked genes on cognition. In addition, experimental
data on eye tracking in X-monosomic females demon-
strated similar results as in males with Asperger
syndrome, implicating the involvement of X linked
genes in the functional integrity of human brain.
An observation on fMRI studies with Klinefelter men
was presented by Rene’ Kahn, from Rudolf Magnus
Institute for Neuroscience, Netherlands. fMRI was used
to explore the effects of an extra X chromosome on
language lateralization. The data presented clearly
suggests that there is decreased language lateralization
in Klinefelter men due to increased activity in the
language areas of the right hemisphere. This was
interesting since loss of language lateralization was
also exhibited by patients suffering from schizophrenia.
Another study on Klinefelter men using structural
MRI was presented by Jay Geidd, from NIMH. The work
highlighted the key difference in structural brain MRI
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imaging of Klinefelter men when compared to healthy
age matched controls. Total cerebral volume and lobar
volumes were smaller in Klinefelter men and lateral-
ventricle volume was larger. The cortex was thinner in
the XXY group in left frontal, temporal, and superior
motor regions. These findings are consistent with
corresponding cognitive and behavioral problems in
Klinefelter men.
Jean Steyaert from Katholieke Universiteit Leuven,
Belgium reported results from a study on XYY syndrome
in children and its clinical implications. A study on boys
with both prenatal and postnatal diagnoses of XYY
revealed that they have an increased prevalence of early
language problems and increased trend for autism
spectrum disorders. This data raises issues about the
direct involvement of the Y chromosome in the social
communicative domain.
Finally, Timothy Crow from Oxford University pre-
sented his thoughts on the involvement of genes within
the X-Y homologous region and hominid evolution. He
concluded that the data from XXY and XYY males were
consistent with involvement of an excess of an X-Y
homologous gene, one that escapes normal X-chromo-
some inactivation and is involved with lateralization of
the brain and language functioning. The human brain
lateralized at some point in evolution and a torque from
right frontal to left occipital was introduced. The torque,
which is the defining characteristic of human brain is
stable across populations, but is epigenetically variable
within populations. Normal torque is diminished or
absent in schizophrenia. This hypothesis proposes that
schizophrenia is a disorder of the genetic mechanisms
that controls the mechanism of cerebral asymmetry.
Psychosis represents an extreme variation that cuts
across populations, relates to cerebral torque, and is
associated with the capacity to acquire language. This
hypothesis is supported by data from the previous
speakers and explains why schizophrenia-like illness
is increased among men with XXY, and possibly men
with XYY syndrome. On the other hand, non-verbal
cognitive deficits and autistic-like behavior are more
frequent in females who lack an X chromosome. He also
noted that by assessing the anatomical asymmetry
(torque) in Klinefelter’s men, a loss of asymmetry
anterior but not much posterior was noted. Whereas in
Turner’s females, an exaggerated occipital asymmetry
to the left was noted and this was consistent with its
respective symptomatology. Klinefelters have verbal
deficits or delays suggesting a left hemisphere dys-
function and Turners have deficits in non verbal
(spatial) ability and relative loss of right hemisphere
function, consistent with relative torque. Finally he
suggested that a brain expressed gene, Protocadherin
X/Y, that has evolved as a uniquely human variant and
in an X-Y homologous chromosomal region escaping
inactivation was a likely candidate for a gene that
contributes to cerebral asymmetry, language and
schizophrenia
A discussion following the presentations and was
chaired by Lynn Delisi. One question raised was
whether it would be important to screen all children
with language problems for chromosomal anomalies like
Klinefelters. However, Jay Giedd cautioned that these
studies reported had enormous bias towards XXY men
who had difficulties, and that he has observed indivi-
duals without language and other cognitive disabilities
who also have an XXY chromosome constitution. He
commented that there are likely to be many unrecog-
nized people with an XXY karyotype in the general
population.
Another issue raised was that of parental origin of the
extra X chromosome in Klinefelters, triple X and X0 and
how this might effect the phenotype. David Skuse
responded with a summary of some of a recent study
he performed involving Klinefelter’s subjects who con-
sisted of 50% paternal-origin to the extra-X and 50%
maternal origin of the extra-X chromosome. Although
the sample was small, unlike his previous report in X0
females, with the XXY males there was no imprinting
effect on cognitive deficits.
In summary, the presentations and the discussions in
this session highlighted the undeniable influence of sex
chromosomes in social cognition, behavior and language
development. It seems important to focus future
research to unravel the molecular basis behind this
phenomenon.
19. EPIGENETICS
Reported by Jonathan Mill
It is becoming increasingly apparent that there is more
to the genome than the series of nucleotides making up
our DNA sequence. Sitting above the DNA sequence is a
second layer of information (the ‘‘epigenome’’) control-
ling gene expression and a range of other genomic
functions. Epigenetics refers to the mitotically herita-
ble, but reversible, regulation of gene expression
mediated principally through modifications of DNA
and histones (Henikoff and Matzke, 1997). Such
epigenetic processes are essential for normal cellular
development and differentiation, and allow the
regulation of gene function through non-mutagenic
mechanisms. It has been postulated that epigenetic
dysregulation could explain the many epidemiological,
clinical, and molecular peculiarities associated with
psychiatric phenotypes that are hard to rectify using
traditional gene- and environment-based approaches
(Mill and Petronic, 2007). A dedicated epigenetics
plenary symposium at this years’ World Congress of
Psychiatric Genetics Meeting included talks from four
distinguished researchers who introduced some basic
epigenetic processes and discussed their potential
importance within the context of psychiatric disease.
Whilst epigenetic research in psychiatry is in its infancy,
and few empirical studies have been performed to date,
there was also an interesting poster session, with
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several studies attempting to link DNA methylation
changes to psychiatric phenotypes.
The first speaker at the plenary symposium was
James Potash from the Center for Epigenetics at Johns
Hopkins University School of Medicine, whose talk
focused on a study that he and his colleagues have
performed investigating DNA Methylation signatures
within the human brain. We actually know very little
about what comprises a ‘normal’ epigenome, and how
epigenetic marks such as DNA methylation differ
between tissues. This is one of the targets of the Human
Epigenome Project (www.epigenome.org), which aims to
map all methylation variable positions in the genome
(Eckhardt et al., 2006). For future etiological studies in
psychiatric disorders, it will be important to map brain-
region specific epigenetic differences. In research cur-
rently ‘in press’ in the American Journal of Human
Genetics, Dr Potash and colleagues investigated 1,505
CpG sites, representing 807 genes, in brain samples
from the cerebral cortex, cerebellum, and pons. Analysis
of their data showed distinct tissue-specific clustering,
and allowed them to identify specific DNA methylation
signatures that could distinguish between these three
regions.
Mounting evidence suggests that epigenetic processes
may be induced following exposure to a range of
environmental insults. DNA methylation, for example,
has been shown to vary as a function of numerous
nutritional, chemical, physical, and psychosocial factors
(Feil, 2006). Such dynamic epigenetic changes were the
focus of a presentation by Emma Whitelaw from the
Queensland Institute of Medical Research in Australia.
She discussed the importance of so-called ‘metastable
epialleles’ – loci that can be epigenetically modified to
produce a range of phenotypes from genetically identical
cells (Rakyan et al., 2002). Many of these loci have been
shown to be environmentally regulated; one classic
example is the agouti viable yellow allele in mice, in
which a promoter-region transposon can be epigeneti-
cally altered by manipulating the diet of pregnant
females, directly affecting expression of the agouti gene
and producing a wide distribution in offspring coat
color phenotypes ranging from yellow (unmethylated)
to brown (methylated; Cooney et al., 2002). It was
traditionally believed that epigenetic profiles are reset
and erased during gametogenesis, thus preventing the
meiotic transmission of epigenetic information between
generations. Dr Whitelaw reviewed mounting evidence
to suggest that such notions may be incorrect – i.e. the
epigenetic marks of at least some mammalian genes
may not be fully erased during meiosis and could be
passed transgenerationally. Although still to be proven
in humans, her group’s studies on animals demonstrate
that, at least for some loci, the epigenetic state may be a
record of environmental history, including that of
previous generations.
Dolores Malaspina, from the Department of Psychia-
try at New York University, introduced the idea that
aberrant epigenetic regulation could explain the rela-
tionship between increasing paternal age and the risk of
developing schizophrenia. There are now numerous
published replications of her initial data uncovering a
three-fold increased risk for offspring of fathers aged
over 50 compared to those aged less than 25 years
(Malaspina et al., 2001). These cases may account for
most sporadic schizophrenia cases, and may comprise a
specific subtype of the disease. Given that advancing age
and environmental influences have been linked to
epigenetic dysfunction, she proposed that epigenetic
dysregulation could be the mechanism behind the
effects of paternal age. Her group is currently involved
in some intriguing animal studies that have found quite
distinct phenotypic changes in inbred mice differing
only in paternal age. Interestingly, the offspring of these
animals reverted to wild-type behaviors, suggesting
that these phenotypic effects were not caused by DNA
sequence mutations.
The final talk was by Carmen Sapienza from Temple
University School of Medicine in Philadelphia, who
discussed the importance of interindividual epigenetic
variation. His group has used longitudinal studies to
track changes in X-chromosome inactivation and geno-
mic imprinting over the life-course, and found evidence
that both these become increasingly unstable with age.
Of particular interest to psychiatric phenotypes, Dr
Sapienza’s team has found evidence that DNA methyla-
tion in the MAOA gene is highly variable between
individuals. He proposed that determining the epigen-
otype of a gene could provide additional information to
that obtained from looking at simple DNA-sequence
based changes.
A number of interesting epigenetic posters were also
presented at this year’s WCPG. Following previous
reports suggesting that epigenetic changes in the reelin
gene may be associated with schizophrenia (Grayson et
al., 2005), Mamoru Tochigi, Tadafumi Kato, and
colleagues from the University of Tokyo attempted to
replicate this finding using fully quantitative methyla-
tion profiling methods but were unable to detect any
schizophrenia-associated changes. Optimal methodolo-
gical approaches for DNA methylation studies are still
being developed, and the Japan study highlights how
some of the methods used in previous studies, for
example methylation-specific PCR, could potentially
lead to the biased assessment of methylated cytosines.
Dirk Moser, Jobst Meyer, and colleagues from the
University of Trier in Germany presented evidence
suggesting that a transcription-factor binding site in
the glucocorticoid receptor gene exon 1-F promoter,
which is epigenetically altered by maternal care in rat
pups (Weaver et al., 2004), is not methylated in the
human hippocampus, replicating previous analyses of
this region performed on lymphocytes and cerebellum
tissue (Mill et al., 2005). Jonathan Mill, Arturas
Petronis and colleagues from the Centre for Addiction
and Mental Health in Toronto presented findings from
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the first comprehensive microarray-based epigenomic
study of major psychosis using DNA obtained from the
frontal cortex. They reported evidence for psychosis-
associated DNA methylation differences in numerous
loci, including several involved in glutamatergic and
GABAergic neurotransmission, brain development, and
other processes functionally-linked to disease etiology.
Finally, Go Kuratomi, Tadafumi Kato, and colleagues
from RIKEN presented data from their investigation of a
pair of monozygotic twins discordant for bipolar dis-
order. They found evidence for decreased DNA methyla-
tion upstream of the gene PPIEL, and a strong inverse
correlation between gene expression and methylation
levels.
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20. GENE-ENVIRONMENT INTERACTIONS
Reported by Heather Volk
A model was proposed for trans-synaptic effects in the
development of a severe form of Attention Deficit
Hyperactivity Disorder (ADHD) combining known
genetic and environmental risk factors. The data used
were from the Missouri Twin Sample, a population-
based sample of twin youth ascertained from birth
records in the state of Missouri (Neuman et al., 2005).
Severe combined type ADHD (SC) was determined by
probabilistic assignment using latent class analysis as
described previously (Neuman et al., 2005). The authors
examined risk for SC due to a VNTR in the 30 region of
the dopamine transporter gene (DAT1), an exon repeat
in the dopamine D4 receptor gene (DRD4), and a SNP in
the cholinergic receptor, nicotinic, alpha 4 (CHRNA4)
gene. SC risk as a result of prenatal exposure to nicotine
was also examined. The authors previously reported
significant two-way interactions between DRD4, DAT1,
and prenatal smoking (Neuman et al., 2007). Addition-
ally a significant two-way interaction between CHRNA4
and prenatal smoking was found to increase the odds of
combined subtype ADHD compared to more mild ADHD
(fewer symptoms;Todd and Neuman 2007). Three way
interactions with the two dopamine genes and prenatal
smoking further increased the odds of combined subtype
ADHD. A four-way interaction test indicated a further
significant increased in the odds of combined subtype
ADHD. The authors conclude a trans-synaptic effect of
dopamine in combined subtype ADHD. The genes
examined here produce products that are in close
proximity. CHRNA4 and DAT1 are pre-synaptic while
DRD4 is post-synaptic and dopamine is a known
morphagen. Thus, these results suggest that dopamine
release may be influenced by exposure to nicotine.
In another study, interactions were examined be-
tween genotypes of the catecholamine pathway and
environmental lead and manganese exposure in a
sample of 150 ADHD children (47 inattentive, 50
combined, 53 controls). Blood plasma levels of lead and
manganese were determined and ADHD was assessed
by a semi-structured clinical interview. In addition to a
diagnosis of ADHD, each child underwent testing for
cognitive control (using the stop task) and reaction time
variability (using the stop signal task). Analyses were
conduced using linear regression. Genotypes examined
were DAT1, DRD4, the adrenergic alpha 2 receptor
(ADRA2A), and dopamine beta hydroxalyse (DBH). No
genetic main effects were found for ADHD or cognitive
processes. Exposure levels of lead and manganese were
similar to the national average. However, significant
correlations between lead exposure and the inattentive
and hyperactive symptoms were found; no significant
correlations were found between the environmental
exposures and the genes examined. There was a
significant increase in lead exposure for the combined
subtype of ADHD compared to inattentive ADHD and
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controls. When a composite variable of having any of the
risk alleles of the four genes was created, statistically
significant effects were found for this genetic composite
and lead exposure for increased risk for reaction time
variability scores. Significant effects were also found
with number of hyperactive symptoms, DBH, and lead.
No significant effects were found for inattentive symp-
toms. However, risk for inattentive symptoms was
increased for lead exposure. Cognitive control appears
to be a mediator between lead and ADHD. Lead
exposure is a risk factor for inattention, significantly
mediated by cognitive control, but only when a genetic
risk is present. Additionally, manganese exposure is
associated with hyperactivity, and mediated by cogni-
tive control, only when genetic risk is present (Nigg et
al., 2007).
In a third report, the interplay of adverse life events
and familial depression liability in predicting the first
onset of a major depressive episode (MDE) was exam-
ined. Subjects were assessed for psychiatric conditions
at baseline and at three follow up points.:1) separation
(ex: death or divorce), 2) trauma (ex: war, a physical
threat, rape or natural disaster, and 3) any severe event
as determined by criteria for post traumatic stress
disorder (PTSD). Subjects were excluded if there was
evidence of lifetime major depression before baseline
examination. Family history of depression and adverse
events were both significantly associated with develop-
ment of depression. When stratified by familial depres-
sion liability, adverse events predicted a substantially
increased incidence of MDE among respondents with
familial liability, but not in those without (Zimmermann
et al., in press).
When examining these risk factors additively, having
both a positive family history and experiencing an
adverse event increased risk for first major depression
beyond either family history or adverse events alone.
The last report focused on increased risk for alcohol-
ism by an interaction of variation in the corticotropin-
releasing-hormone (hCRHR1) gene and adverse life
events. Two independent cohorts were used. The first,
the Mannheim Study of Risk Children, was an adoles-
cent sample with little known exposure to alcohol. The
second was a sample of alcohol dependent adults.
Fourteen SNPS in the hCRHR1 gene were typed in all
subjects. Two haplotypes were detected and each tagged
by a single SNP. They were then examined for associa-
tion with alcohol dependence phenotypes in both
samples. Both haplotypes were significantly associated
with lifetime prevalence of binge drinking and drunken-
ness in the adolescent sample. Additionally, subjects
homozygous for the C allele were at increased risk to
drink more than T carriers when exposed to increasing
numbers of negative lifetime events. In this study,
CRHR1 appears to moderate the effect of stress on
heavy drinking behavior. Life events, used here as the
measure of stress, only affects risk among individuals
with these haplotypes (Blymeyer et al., 2007).
References
Blymeyer D, Treutlein J, Esser G, Schmidt et al. 2007.
Interaction between CRHR1 gene and stressful life
events predicts adolescent heavy alcohol use. Biol
Psychiatry [Epub ahead of print].
Nigg JT, Knottnerus GM, Martel MM, Nikolas M, et al.
2007. Low blood lead levels associated with clinically
diagnosed attention deficit/hyperactivity disorder and
mediated by weak cognitive control. Biol Psychaitry Sep
12 [Epub ahead of print].
Neuman RJ, Lobos E, Reich W, Henderson CA, et al.
2007. Prenatal smoking exposure and dopaminergic
genotypes interact to cause a severe ADHD subtype.
Biol Psychatiry 61:1320–1328.
Neuman RJ, Sitdhirasksa N, Reich W, Ji TH, et al. 2005.
Estimation of DSM-IV an latent class-defined ADHD
subtypes in a population-based sample of child and
adolescent twins. Twin Res Hum Genet 8:392–401.
Todd RD, Neuman RJ. 2007. Gene-environment inter-
actions in the development of combined type ADHD:
Evidence for a synapse-based model. Am J Med Genet B
Neuropsychiatr Genet [Epub ahead of print].
Treutlein J, Kissling C, Frank J, Wiemann S, Dong L,
Depner M, Saam C, Lascorz J, Soyka M, Preuss UW,
Rujescu D, Skowronek MH, Rietschel M, Spanagel R,
Heinz A, Laucht M, Mann K, Schumann G. 2006.
Genetic association of the human corticotropin releasing
hormone receptor 1 (CRHR1) with binge drinking and
alcohol intake patterns in two independent samples.
Mol Psychiatry 11(6):594–602.
Zimmermann P, Brückl T, Lieb R, Ising M, Beesdo K,
and Wittchen H.-U. in press. The interplay of familial
depression liability and adverse life events in predicting
the first onset of depression during a ten-year follow-up.
Biological Psychiatry.
21. ANIMAL MODELS
Reported by Michael J. Galsworthy
The animal models session brought together a diverse
set of studies focused on mechanisms of gene action in
psychiatric genetics. As with all ‘animal models’ of
psychiatric disorders, the aim is not to generate autistic,
schizophrenic, or depressed animals which suffer from
the same higher-level cognitive disturbances as human
sufferers. Rather, the link between a gene and a human
behavioral or cognitive phenotype traverses a web of
complex interactions and animal models regularly
provide powerful tools to begin exploring that web in a
systematic way. As the six talks in this session clearly
demonstrated, animal models provide resources ran-
ging from the development of new gene-therapy tools, to
close analysis of specific genes in terms of all their
consequences and interactions, to separation of self
versus maternal genetic developmental effects, to
nominations of new genes. Simply put, animal models
allow not only gene-hunting via natural or artificial
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variation, but they also allow the added benefits of
controlled experimental systems in which theories can
be explicitly tested and explanatory models built step-
by-step.
Three of the six talks focused on modeling key
neuroscience components of schizophrenia in the mouse
brain. Two talks explored the functioning of serotonin
via variations in associated genes, and one talk
described a project aimed at generating a toolbox of
brain region-specific lightweight promoters.
The first talk introduced the Pleiades Promoter
Project (www.pleiades.org), which aims to generate a
public resource of 160 human DNA MiniPromoters
(under 4 kb in size each) to allow gene expression specific
to brain regions of therapeutic interest. Elizabeth
Simpson from the Centre for Molecular Medicine and
Therapeutics, Vancouver, Canada, explained the key
purpose of the project: The once highly popular area of
gene therapy seems not to have delivered on its early
hype. A major problem has been the lack of specificity of
attempts so far; specificity in terms of clinical relevance,
of insertion site and of gene expression. The talk
centered on how such issues could be addressed and
outlined progress so far. Essentially, the project’s
structure is to go from selection of genes which show
region-specific expression through stages of promoter
design and promoter construction whilst testing expres-
sion in knock-in mice and tailoring the specificity to ever
more differentiated regions of therapeutic interest.
Some 30 regions of interest were chosen (including the
blood-brain barrier), and through consultations of
SAGE libraries, a list of 2780 genes was screened down
to 70 that were used. The endeavour not only aims to
provide the scientific community with new flexible tools,
but also remains open to collaboration and nomination of
genes of priority. If interested in this work, please visit
the website cited above.
As mentioned above, half the talks in the session
concerned the characterization of genes potentially
involved in schizophrenia. Looking at the strong
contributions from each of these, it is tantalizing to
think how these interacting genes and proteins nomi-
nated by various methods might be slowly pulled
together to explain not only key properties of the
disorder, but also the mechanisms underlying the drug
responses, and drug response differences across indivi-
duals. The talk by David Porteous from the University of
Edinburgh (with coauthors also from Canada and
Japan) demonstrated neatly how genes which have
been implicated by human psychiatric research can be
explored in mouse models so as to investigate neuro-
anatomical, behavioural and drug-response conse-
quences within a controlled framework. The study
focused on DISC 1 (Disrupted in Schizophrenia 1), a
gene with one of the most replicated connections with
schizophrenia in the human literature. An ENU screen
for missense mutations in the mouse Disc1 identified
two mutations in Exon 2. The two strains, Q31L and
L100P, both suffered from shrinkage of the brain, lower
prepulse inhibition (PPI) and lower latent inhibition
(LI), similar to human neurospychiatric findings. Anti-
psychotic and antidepressant drugs could reverse some
of the symptoms, but a particularly interesting distinc-
tion was the differential response between Q31L and
L100P to the drug rolipram, a phosphodiesterase-4
(PDE4) inhibitor. In fact, closer examination of the
DISC1 binding partner PDE4B nominated PDE4 as a
potential source of the Q31L characteristics of depres-
sion and resistance to rolipram. The study now aims to
explore how missense mutations in close proximity in
DISC1 provide different phenotypes by differential
interaction with key interacting genes/proteins.
Similarly, the talk by Kevin Mitchell from Trinity
College Dublin, explored anatomical, behavioural and
pharmacological consequences of mutations in Sema6A
(a transmembrane semaphorin) and two interacting
proteins; PlexinA2 and A4. Semaphorin and Plexin
proteins have been associated schizophrenia (and other
cognitive disorders) and are believed to be important in
the development of connectivity in the brain. The
mutants deficient in these proteins showed a variety of
axon guidance and cell migration defects, including in
regions which have been implicated in schizophrenia.
Behavioural tests showed hyperlocomotion and working
memory deficits (spontaneous alternation in a T-maze)
and cortical EEG recordings showed increased power in
the alpha band. As with the findings from David
Porteous’ group, antipsychotic treatment reversed
many symptoms and so provided an extra level of
support for the relevancy of the model.
The third talk in the trio focusing on the neuroscience
of schizophrenia genes in the mouse was given by Tracey
Petryshen from the Broad Institute in Cambridge, USA.
This group had previously discovered three QTLs
associated with prepulse inhibition (PPI) in the mouse,
and were now using congenic lines to reduce locus
boundaries, then nominate positional candidate genes
with bioinformatic resources, then finally explore those
top candidates using knockout, knockdown and phar-
macologic studies. All three loci were reduced to less
than 3Mb in size before transcript and expression data
and neural circuitry information implicating a PPI role
were queried to nominate likely candidates within the
regions. In particular, two candidates were nominated
for detailed study; Protein kinase C alpha (Prkca) and
Rgs9.
The talk by Jacques Mallet from CRNS, Paris, began
with a riddle. Although there is much evidence for a
developmental role for serotonin in the prenatal brain
before it later becomes a neuromodulator/neurotrans-
mitter, nevertheless no sites of early serotonin biosynth-
esis have been discovered in the mouse embryo brain.
With the hypothesis that the serotonin could be of
maternal origin, the group crossed mice lacking tph1,
a gene responsible for the synthesis of peripheral
serotonin. The very striking finding was that although
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tph1 / mice developed normally, the embryos of
tph1 / mothers (but not embryos of wildtype mothers
and tph1 / fathers) showed very abnormal develop-
ment. The implications of the findings are very far-
reaching as there have been cases where genotypes
have been associated with phenotypes but the mechan-
isms have proven elusive. It was directly suggested
in this talk that there may be cases where genotypes
are correlated with phenotypes only by virtue of
the genotype correlating with the mother’s genotype,
which in turn is the true origin of the phenotype.
Should it be the case that an individual’s propensity
to psychiatric disorder lies in aspects of their early
brain development, and this development in turn is
caused at least in part directly by the mother’s genotype,
then this would appear to open an exciting new domain
of study in developmental genetics and psychiatric
genetics.
The final talk in the session differed from the others in
that it used primates rather than mice as its subject of
study. Ned Kalin from the University of Wisconsin
explained that rhesus monkeys, like humans, have a
promoter repeat polymorphism in the serotonin trans-
porter gene. In humans, this SLC6A4 promoter repeat
polymorphism has been associated with anxiety and
increased amygdala response. Therefore this study
examined differences between ’short’ and ’long’ alleles
in rhesus macaque juveniles in response to differing
levels of stress. These levels were; baseline in their home
cages, alone in a cage, or alone and presented with the
profile of a human stranger (but with no eye contact).
Images from high-resolution FDG microPET following
the challenges showed that although there were no
differences in baseline recordings, the ’short’ allele
juveniles showed more activation in anxiety-relevant
brain locations such as the amygdala and orbitofrontal
cortex (OFC) during the stronger challenges. Thus the
studies not only provided evidence for the link between
the serotonin transport and anxiety in a parallel species,
but also provided a nice demonstration of the elicitation
of allelic differences by changing environmental circum-
stances.
In summary, there was both convergence and great
divergence in this series of talks. The convergence in
the schizophrenia genes being uncovered and investi-
gated in the mouse brain gave promise of the sophisti-
cated integrated models that are surely to come.
The divergence in the roles of serotonin, one inves-
tigating gross brain deficits caused by lack of maternal
serotonin and the other demonstrating the subtle
interplay of genetic variants with very short time
periods of environmental stress, remind us of the vast
interactive complexity we are attempting to explore.
Finally, the development of gene-therapy tools using
knowledge of differential expression patterns in the
brain indicates how in the future we might begin
converting disease genes from objects of study to tools
of medicine.
22. FROM GENES TO DRUGS: WHAT ARE
THE OBSTACLES
Reported by Petra Zimmermann, Ph.D.
A panel discussion was led by Alan Cross and Hugh
Salter from Astra Zeneca in the hope of a stimulating a
dialogue about how both companies and academia could
work together in academic-industry collaborations.
Suggestions were solicited for optimizing future col-
laboration. The panel included representatives from
other pharmaceutical companies, as well as academia
and the federal government.
The majority of medicines today are aimed at treating
the symptoms of disease rather than the underlying
causes. Genetics offers the possibility to gain insight into
the biological mechanisms of complex diseases such as
schizophrenia. By identifying key susceptibility genes
we will be able to study the encoding proteins and to
discover the underlying biological mechanisms of the
disease. Drugs targeting key elements in the pathway
may be effective tools to disrupt pathogenic processes.
However, due to fast technical developments, the avail-
ability of genome-wide studies, and the consequentially
growing complexity of analysis, the translation of
findings in schizophrenia genetics into effective drugs
is a considerable challenge. This could make the
initiation and development of collaborative strategies
between academia and industry even more essential
since they could provide extended power to gain more
knowledge on topics as the exploration and validation
of more drug targets, the identification of surrogate
markers and modulators of response to a drug, and the
development of a individualized and targeted medi-
cine – to mention only a few.
Hugh Salter introduced the session with a talk on
‘‘Psychiatric genetics and drug involvement’’, and asked
the broad question of how psychiatric genetics could be
used for drug discovery. An ideal approach he said
should be based on two hypotheses: First, biologically-
explainable single or combinatorial markers predict the
risk of being affected by a specific disease and second,
susceptibility genes can help to identify novel routes for
interventions. However, the ultimate use of genetics will
take considerable time because of concerns over replica-
tion and validity, and the fact that novel targets are not
processed with rapidity. Thus, there is a gap between
what is ideal and the actual situation, aside from being
due to the long time it will take to use genetic dis-
coveries, the costs, the scientific rationale may be
difficult to prove, many of the genes found may have
small effect sizes, and disease rather than drug response
is being currently assessed. It remains to be seen, if
genome-wide analyses will give the answers. The
question of how this gap could be bridged is closely
related to the question of how industry and academia
could work together. The establishment of a community
for sharing results and resources is needed (e.g., sharing
of DNA from pharmaceutical trials, pooling samples for
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replication, sharing data for meta-analyses, and system
biology collaborations). The feasibility, desirability, and
organisation of such collaborations were discussed at
this session and deserve further discussion by the field
in the future.
David Porteous (Chair of Human Molecular Genetics
& Medicine, Medical Genetics Section, University of
Edinburgh, UK) focused on ‘‘From genes to target – how
will this happen?’’. Can gene discovery lead to biomarker
discovery and ultimately drug target development.
Problems that exist with current drugs include the
unresponsiveness of one third of patients, several
unacceptable side effects, or weak pharmacological
rationale. In psychiatric genetics, we have clear evi-
dence that genes are important, but many aspects of the
genetics are still unclear, i.e. the genetic architecture of
specific diseases, the contribution of common and/or rare
genetic variants, whether these diseases are dichoto-
mous or along a spectrum, and whether unique or
common underlying traits play a role. Lessons could be
learned from Alzheimer’s Disease where multiple genes
(e.g. ApoE4, APP, PS1, PS2) are relevant. Thus, the
following sequential gene based strategy was suggested:
take any gene of which you have evidence for causality in
an individual, family, or population, work out its biology,
develop a cell based assay, identify its therapeutic effect,
test the effects in animal models, conduct a trial in
genetically susceptible human subjects, and test for
generalisability.
As multiple independent genetic linkage and associa-
tion studies provide confirmatory evidence for involve-
ment of the disrupted in schizophrenia (DISC1) gene in
schizophrenia (e.g., Blackwood et al., 2001; Harrison &
Weinberger, 2005; Millar et al., 2000), DISC1 was
discussed as an example of a target for further research.
DISC1 interacts with proteins required for neurodeve-
lopment and neuronal function: The gene encoding
phosphodiesterase 4B (PDE4B) is disrupted by a
balanced chromosomal translocation on Chromosome 1
in a subject diagnosed with schizophrenia. PDE4B, in
turn, inactivates intracellular cyclic adenosine mono-
phosphatase (cAMP), which is a key second messenger
in the brain involved in learning and memory processes
as well as mood. Millar and colleagues (2005) found
interactions between DISC1 and the UCR2 domain of
PDE4B and they could show that increases in cellular
cAMP are followed by a dissociation of PDE4B from
DISC1 and an elevation in PDE4B activity (Millar et al.,
2005). Clapcote and colleagues (2007) then demon-
strated that two independent missense mutations in
mouse DISC1 evoke distinct physiological, pharmacolo-
gical, neuroanatomical, and behavioural phenotypes.
Murdoch et al. (2007), furthermore, revealed that
DISC1-PDE4 interaction is isoform specific. Overall,
DISC1 has multiple functional motifs and interaction
domains, multiple targets for mutation and modulation,
and mutation class specific effects. It is a scaffold
protein regulating key neurodevelopmental and neuro-
signaling proteins. Therefore, there is emerging evi-
dence that DISC1 is as a common genetic and
biologically plausible risk factor for major mental illness
such as schizophrenia and depression. The investigation
of DISC1 mechanisms provides the opportunity for a
better understanding of these complex disorders which
is a prerequisite to the development of rational and
effective interventions. Next steps to elucidate the
DISC1 pathway should be genomic resequencing,
development of more mouse models, refinement of
biomarkers and endophenotypes, and drug discovery,
genetic and chemical phenotypic rescue, and replication
of this process. To increase the possibility of success, the
specification of common goals with industry is essential.
Bryan DeChairo from Pfizer, dealt with the topic
‘‘Genetic markers for efficacy and safety in psychiatric
drugs – what is the potential?’’. He focused on the
potential of genetic markers a) to increase the efficacy
and b) to enhance the safety of psychiatric drugs. While
the first point aims to identify novel therapeutics
targeted for patients with an unmet medical need, the
second point has the goal to exclude ‘‘at risk patients’’
from treatment when alternative treatments exist and
to proceed towards individualized, tailored medicine.
One of the problems addressed was that the predict-
ability of biomarkers has to be extremely high. It was
concluded that biomarkers should be examined over
time and a combination of multiple markers could yield
some advantage.
Possibilities for overcoming barriers between indus-
try and academia that have existed in the past were
discussed and commitments for future collaborations
offered, despite the different ultimate purposes of
commercial companies versus academia. The competi-
tion between companies and the lack of previous open-
ness would have to be overcome. Other issues discussed
were different timing of public sharing between indus-
try and academia, the difficulties of contractual agree-
ments with different academic versus industry criteria
for intellectual property rights and other agreements. In
summary, the workshop made evident that - even if
various problems exist with industry-academic partner-
ships in psychiatric genetics, they should be encouraged
in order to enhance the power to gain new insight into
the underlying pathogenic mechanisms of disorders, to
elucidate new ways for mechanism-based and indivi-
dualized interventions, and to considerably improve the
translation of these research findings into new ther-
apeutics.
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